

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using bw model

Run on: January 26, 2005, 12:54:26 ; Search time 191 Seconds

(without alignment)
777.208 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MMSGAVLRVLRNRPQAVLM.....SVLQDQMPYQNAQAQKVA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: uniprot_sprot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1386	98.1	273	1	GFR4_RAT
2	1075.5	54.3	260	1	GFR4_MOUSE
3	767.5	54.3	259	1	GFR4_HUMAN
4	585.5	41.4	431	1	GFR4_CHICK
5	476.5	33.7	481	2	Q98T78
6	476.5	33.7	481	2	AAK11261
7	471	33.3	330	2	Q922A2
8	469	33.2	358	2	Q922A3
9	469	33.2	444	2	Q792X9
10	469	33.2	464	2	Q35977
11	465	32.9	463	1	GFR2_MOUSE
12	465	32.9	463	2	Q920Y3
13	465	32.9	465	1	GFR1_HUMAN
14	464	32.8	331	2	Q725C2
15	464	32.8	463	2	Q35252
16	464	32.8	468	1	GFR1_MOUSE
17	464	32.8	468	2	Q35246
18	463	32.8	469	1	GFR1_CHICK
19	462	32.7	463	2	Q15748
20	462	32.7	464	1	GFR2_HUMAN
21	462	32.7	464	2	AAH41688
22	462	32.7	464	1	GFR1_RAT
23	460.5	32.6	465	1	GFR2_CHICK
24	459	32.5	472	2	Q98T79
25	459	32.5	472	2	AAK11260
26	434.5	30.8	495	2	Q6T5C3
27	434.5	30.8	495	2	AAK9464
28	366.5	25.9	397	2	AAH66202
29	364.5	25.8	385	2	Q9R2D0
30	364.5	25.8	397	1	GFR3_MOUSE
31	363	25.7	222	2	Q9Q2G2

32	361	25.5	369	2	AA089396	AA089396 homo sapi
33	361	25.5	400	1	GFR3_HUMAN	060609 homo sapien
34	361	25.5	400	2	AA089356	AA089356 homo sapi
35	253.5	17.9	225	2	Q9QWK2	Q9QWK2 mus musculu
36	209.5	14.8	109	2	Q8UG58	Q8UG58 ambystoma m
37	184.5	13.1	394	2	Q6UXV0	Q6UXV0 homo sapien
38	184.5	13.1	394	2	AA088565	AA088565 homo sapi
39	172.5	12.2	1219	2	Q95XG5	Q95XG5 caenorhabdi
40	167	11.8	393	2	Q6S0B0	Q6S0B0 mus musculu
41	167	11.8	393	2	AA513632	AA513632 mus muscu
42	153.5	10.9	502	2	Q7QDE4	Q7QDE4 anopheles g
43	131.5	9.3	744	2	Q8NH02	Q8NH02 homo sapien
44	130.5	9.2	3718	1	LM45_MOUSE	061001 mus musculu
45	130.5	9.2	3775	2	Q7PMF9	Q7PMF9 anopheles g

ALIGNMENTS

```

RESULT 1
GFR4_RAT
ID GFR4_RAT STANDARD; PRT; 273 AA.
AC Q9EP12; Q9EP13;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 05-UTL-2004 (Rel. 44, Last annotation update)
DE GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4)
GN (perlephin receptor).
OS Name=Gfr4;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS A AND B), AND VARIANT ARG-257.
RC TISSUE=Brain, Heart, and Kidney;
RX MEDLINE=20564314; PubMed=10958791; DOI=10.1074/jbc.M003867200;
RA Masure S., Cik M., Hoefnagel E., Nozrat C.A., Van der Linden I.,
RA Scott R., Van Gompel P., Lesage A.S.J., Verhaesselt P., Ibanez C.F.,
RA Gordon R.D.;
RT "Mammalian GFRalpha-4, a divergent member of the GFRalpha family of
RT coreceptors for Glial cell line-derived neurotrophic factor family
RT ligands, is a receptor for the neurotrophic factor perlephin.";
RL J. Biol. Chem. 275:39427-39434(2000).
CC -1- FUNCTION: Receptor for perlephin. Mediates the GDNF-induced
CC autophosphorylation and activation of the RRT receptor. May be
CC important in C-cell development and, in the postnatal development
CC of the adrenal medulla.
CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
CC (isoform A). Secreted (isoform B) (Potential).
CC -1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Comment=Additional isoforms seem to exist;
CC Name=A;
CC Name=B;
CC IsoId=Q9EP12-1; Sequence=Displayed;
CC -1- TISSUE SPECIFICITY: Weakly expressed in heart, brain and testis.
CC -1- SIMILARITY: Belongs to the GDNFR family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; AJ294475; CAC16420.1; -
CC EMBL; AJ294476; CAC16421.1; -
CC RGD; 620503; Gfr4.
CC InterPro; IPR003438; GDNF_receptor.
CC Pfam; PF02351; GDNF; 1.

```

DR PRINTS: PRO1316; GDNF RECEPTOR.
 KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
 KM Polymorphism; Receptor; Signal.
 FT SIGNAL 1 ? Potential.
 FT CHAIN ? 250 GDNF family receptor alpha 4.
 FT PROPEP 251 273 Removed in mature form (Potential).
 FT CARBOHYD 192 192 N-linked (GlcNAc...) (Potential).
 FT LIPID 250 250 GPI-anchor amidated asparagine (Potential).
 FT VARSPLIC 253 273 CCFWVSSMSITLALALQALL -> QAKVEA (in isoform B).
 FT VARIANT 257 257 /FTId=VSP_007230.
 FT SEQUENCE 272 AA; 29682 MW; EOBH76ABE2AC6B04 CRC64; W -> R (in 50% of the molecules).
 Query Match 98.1%; Score 1386; DB 1; Length 273;
 Best Local Similarity 100.0%; Pred. No. 1.2e-109;
 Matches 252; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLSGAYLRVNERPGQAVLMSLGQSGASSTEGRCVEAAEACTADECCQQRSEYVAQ 60
 DB 1 MLSGAYLRVNERPGQAVLMSLGQSGASSTEGRCVEAAEACTADECCQQRSEYVAQ 60
 QY 61 CLGPAWPGSGCVRSRCRRALRRFPARGPALTHALPCGCEGPACAEERRQTPAPAC 120
 DB 61 CLGPAWPGSGCVRSRCRRALRRFPARGPALTHALPCGCEGPACAEERRQTPAPAC 120
 QY 121 FSGQLAPSPGLKRLDCESRRRCRPLFAFQASCAPAPSGRCPEEGSPCLRAVAGL 180
 DB 121 FSGQLAPSPGLKRLDCESRRRCRPLFAFQASCAPAPSGRCPEEGSPCLRAVAGL 180
 QY 181 VGVTVVNYLDNVSARVAWPGCEASGNRRECEAPFKLPTNPCLDGAQADSPQSV 240
 DB 181 VGVTVVNYLDNVSARVAWPGCEASGNRRECEAPFKLPTNPCLDGAQADSPQSV 240
 QY 241 LQDQWNPYQWAG 252
 DB 241 LQDQWNPYQWAG 252

RESULT 2
 ID GFR4 MOUSE STANDARD; PRT; 260 AA.
 AC Q9JUT2; Q9JUT3; Q9JUT4; Q9JUT6; Q9JUT7; Q9JUT8;
 DT 10-OCT-2003 (Rel. 42, Created)
 DT 10-OCT-2003 (Rel. 42, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFR1pha4)
 GN (Perezepin receptor).
 GN Name=Gfr4;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 ON NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORMS A1; A2; A3; B1; B2 AND B3).
 RC TISSUE=Thyroid;
 RX MEDLINE=20319126; PubMed=10680579; DOI=10.1006/mcne.2000.0845;
 RA Lindahl M., Timmusk T., Rosol J., Saarma M., Atraktsion M.S.;
 RT "Expression and alternative splicing of mouse Gfr4 suggest roles in
 endocrine cell development.";
 RL Mol. Cell. Neurosci. 15:522-533 (2000).
 -!- FUNCTION: Receptor for perezepin. Mediates the GDNF-induced
 autophosphorylation and activation of the RET receptor. May be
 important in C-cell development and, in the postnatal development
 of the adrenal medulla.
 -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
 (isoforms a1 and b1). Secreted (isoforms a3 and b3) (Potential).
 -!- ALTERNATIVE PRODUCTS:
 Event=Alternative splicing; Named isoforms=6;
 Comment=Additional isoforms seem to exist. Tissue-specific and,
 developmentally regulated splicing;
 Name=a1;

CC IsoId=Q9JUT2-1; Sequence=Displayed;
 CC Name=a2;
 CC IsoId=Q9JUT2-2; Sequence=VSP_007227;
 CC Name=a3;
 CC IsoId=Q9JUT2-3; Sequence=VSP_007228, VSP_007229;
 CC Name=b1;
 CC IsoId=Q9JUT2-4; Sequence=VSP_007226;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC Name=b2;
 CC IsoId=Q9JUT2-5; Sequence=VSP_007226, VSP_007227;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC Name=b3;
 CC IsoId=Q9JUT2-6; Sequence=VSP_007226, VSP_007228, VSP_007229;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC -!- TISSUE SPECIFICITY: Expressed in many tissues including adrenal
 medulla, brain neurons, with highest levels in the cerebral
 cortex and hippocampus. Moderate levels found in the gut circular
 muscle and myenteric ganglia as well as in other peripheral
 ganglia, including the sensory dorsal root and trigeminal as well
 as superior cervical and sympathetic chain ganglia. Isoform a1,
 isoform a2, isoform b1 and isoform b2 are exclusively found in the
 thyroid, parathyroid and pituitary glands.
 CC -!- DEVELOPMENTAL STAGE: Expressed in several tissues at different
 embryonic and postnatal stages such as the condensing mesenchyme
 of developing bones and developing nervous system. Expressed in
 the developing pituitary gland from E16 and in developing thyroid
 C-cells from E14. In the ventral spinal cord, levels decline
 before birth. In the parathyroid, levels first detected in 3-to 6-
 week-old mice with high expression. In the adrenal medulla,
 expressed only in newborn, postnatal (P08) and adult mice. Isoform
 a1 and isoform b1 are preferentially expressed in 3-week-old
 thyroid, isoform a2 and isoform b2 in newborn and 6-week-old
 thyroid glands as well as in postnatal adrenal and pituitary
 glands.
 CC -!- SIMILARITY: Belongs to the GDNF family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).
 CC EMBL; AJ276870; CAB89690.1; -;
 CC EMBL; AJ276871; CAB89691.1; -;
 CC EMBL; AJ276872; CAB89692.1; -;
 CC EMBL; AJ276514; CAB89687.1; -;
 CC EMBL; AJ276515; CAB89688.1; -;
 CC EMBL; AJ276516; CAB89689.1; -;
 CC MGD; MG11341873; GFr4.
 CC InterPro; IPR003438; GDNF_receptor.
 CC Pfam; PF02351; GDNF, 1.
 CC PRINTS; PRO1316; GDNF RECEPTOR.
 CC Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
 KW Receptor; Signal.
 FT SIGNAL 1 23
 FT CHAIN 24 237 GDNF family receptor alpha 4.
 FT PROPEP 238 260 Removed in mature form (Potential).
 FT CARBOHYD 184 184 N-linked (GlcNAc...) (Potential).
 FT LIPID 237 237 GPI-anchor amidated threonine (Potential).
 FT VARSPLIC 1 17 MAHCEALDLILLGLS -> MURAHLMDEPQAIPLGLT
 FT GSGQRS (in isoform b1, isoform b2 and
 FT isoform b3).
 FT VARSPLIC 245 260 /FTId=VSP_007226.
 FT VMLVLAFTLALQALL -> ARHEWPEKSWKQSLFCGNA
 FT OGVLAVCTHRCSPSPALIRNNRRKHS (in isoform
 FT a2 and isoform b2).
 FT /FTId=VSP_007227.
 FT PRLTAFQASCAPAPSGRCPEEGSPCLRAVAGLIGTVVT
 FT PNVLIDNVSARVA -> CVRAGAGPLTVRARAGVSLPSR
 FT PHALPRPAPATVARRRGARVVCASQAS (in isoform

FT		a3 and isoform b3) .
FT		/FTId=VSP_007228.
FT	VARSPLIC	191 260 Missing (in isoform a3 and isoform b3) .
FT		/FTId=VSP_007229.
SO	SEQUENCE	260 AA; 27990 MW; 2679BBC789E38075 CRC64;
	Query Match	76.1%; Score 1075.5; DB 1; Length 260;
	Best Local Similarity	89.6%; Pred. No. 2.6e-83;
	Matches 198; Conservative	7; Mismatches 13; Indels 3; Gaps 1
Oy		27 GSASSTEGNRCEVAEAECTADQECQOLRSEYVAOCLIGRA--GMRPGSCVYSRCRRALR 83
Dd		16 GSASTDGNCRCDAAAEACTADBRCQQLNSEYVARCLGRNAPCGRGPCGCVRSRRLR 75
Oy		84 RFPARGPALTHALLFCGCEGPACERRRQTQFAPACAFSGPOLADPSCLEKPIDCERSRR 143
Dd		76 RFPARGPALTHALLFCGCEGSACERRRQTQFAPACAFSGPLVPSPCLEPLERCERSL 135
Oy		144 CRPRLEFAOASCAPAPGSRDQEEGGRCARAVGVNGTVTPMYLNVNSARVAPMWC 203
Dd		136 CRPRLEAQAASCAPAPGSRDRPEEGGPPCLKVYAGLLGTVVTPMYLDVNSARVAPMWC 195
Oy		204 EASGNRECECAFRLFTFRNPCLDLDAIOAFDSOSSPSVLDDQ 244
Dd		196 AASGNRECECAFRLFTFRNPCLDLDAIQAFDSLOPSVLDDQ 236
	RESULT 3	
	GFR4_HUMAN	
ID	GFR4_HUMAN	STANDARD; PRT; 299 AA.
AC	Q9GZ27, Q9H191, Q9H192,	
DT	10-OCT-2003 (Rel. 42, Created)	
DT	10-OCT-2003 (Rel. 42, Last annotation update)	
DT	05-JUL-2004 (Rel. 44, Last annotation update)	
DE	GNMF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4)	
DE	(Perserphin receptor).	
CN	Name=GFR4;	
OC	Homo sapiens (Human).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
OX	NCBI_Taxid=9606;	
RN	[1]	
RP	SEQUENCE FROM N.A. (ISOFORM GFRALPHA4A, GFRALPHAB AND GFRALPHA4C),	
RP	AND GPI-ANCHOR.	
RC	TISSUE=Thyroid;	
RX	MEDLINE=21153758; PubMed=1116144; DOI=10.1074/jbc.M008279200;	
RA	Lindahl M., Poteryayev D., Yu L., Annuae U., Timmusk T., Bongartzon I.,	
RA	Atiello A., Pierotti M.A., Alrikainen M.S., Saarna M.;	
RT	"Human glial cell line-derived neurotrophic factor receptor alpha4 is	
RT	the receptor for persephin and is predominantly expressed in normal	
RL	J. Biol. Chem. 276:9344-9351(2001).	
RN	[2]	
RP	SEQUENCE FROM N.A. (ISOFORM GFRALPHA4A).	
RA	Zhou B., Levinson B., Glitschler J.;	
RL	Submitted (Apr-2000) to the EMBL/GenBank/DBJ databases.	
RN	[3]	
RP	SEQUENCE FROM N.A.	
RX	MEDLINE=21638749; PubMed=11780052; DOI=10.1038/414865a;	
RA	DeJonckheere F., Matthews L.H., Asnzure J.L., Burton J., Gilbert J.G.R.,	
RA	Jones M., Stavrakas G., Almeida J.P., Babage A.K., Baggailey C.L.,	
RA	Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,	
RA	Beasley O.P., Bird C.P., Blakey S.E., Bridgman A.M., Brown A.J.,	
RA	Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,	
RA	Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,	
RA	Clegg S., Cobley V.E., Collier R.E., Connor R.E., Cory N.R.,	
RA	Coulson A., Coville G.J., Deadhan R., Dhali P.D., Dunn M.,	
RA	Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,	
RA	Graham D.V., Griffiths C., Griffiths M.N.D., Gilliam R., Hall R.E.,	
RA	Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,	
RA	Huckle E., Hunt A.R., Hunt S.B., Jekesch K., Johnson C.W., Johnson D.,	
RA	Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,	
RA	Lehvaeslaho M.H., Levertha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,	

RA	Marsh V.L., Martin S.L., McConachie L.J., McLay K., McMurray A.A.,
RA	Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA	Oliveira S.A., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA	Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsey H.,
RA	Rice C.M., Ross M.T., Scott C.E., Shera H.K., Shownken R., Sims S.,
RA	Swann C.D., Smith M.L., Soderlund C., Steward C.A., Sutton J.E.,
RA	Sween R.M., Symcox N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA	Tracey A., Tromans A.C., Vautin M., Wall M., Wallis J.W.,
RA	Whitehead S.U., Whitcaker P., Willey D.L., Williams L., Williams S.A.,
RA	Wilmshurst, Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA	Rogers J.;
RT	"The DNA sequence and comparative analysis of human chromosome 20.";
RL	Nature 414:865-871(2001).
CC	-1- FUNCTION: Receptor for persephin. Mediates the GDNF-induced
CC	autophosphorylation and activation of the RET receptor. May be
CC	important in C-cell development and, in the postnatal development
CC	of the adrenal medulla.
CC	-1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
CC	(isoforms GFralpha4a and GFralpha4b). Secreted (isoform
CC	GFralpha4c).
CC	-1- ALTERNATIVE PRODUCTS:
CC	Event=Alternative splicing; Named isoforms=3;
CC	Comment=Additional isoforms seem to exist;
CC	Name=GFralpha4b;
CC	IsoId=Q9GZT7-1; Sequence=Displayed;
CC	Name=GFralpha4a;
CC	IsoId=Q9GZT7-2; Sequence=VSP_007223;
CC	Name=GFralpha4c;
CC	IsoId=Q9GZT7-3; Sequence=VSP_007224, VSP_007225;
CC	-1- TISSUE SPECIFICITY: Predominantly expressed in the adult thyroid
CC	gland. Low levels also found in fetal adrenal and thyroid glands.
CC	-1- SIMILARITY: Belongs to the GDNFR family.
CC	-----
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration
CC	between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC	the European Bioinformatics Institute. There are no restrictions on its
CC	use by non-profit institutions as long as its content is in no way
CC	modified and this statement is not removed. Usage by and for commercial
CC	entities requires a license agreement (See http://www.isb.ch/announce/
CC	or send an email to license@isb-sib.ch).
CC	-----
DR	EMBL; AJ291673; CACI9690.1; -
DR	EMBL; AJ291674; CACI9691.1; -
DR	EMBL; AJ291675; CACI9692.1; -
DR	EMBL; AF253318; AAC25925.1; -
DR	EMBL; AL356755; CACI6508.2; -
DR	Genew; HGNC:13821; GFRA4.
DR	InterPro; IPR003438; GDNF_receptor.
DR	Pfam; PF02351; GDNF; 1.
DR	PRINTS; PR01316; GDNFRECEPTOR.
KW	Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
KW	Receptor; Signal.
FT	SIGNAL 1..20 Potential.
FT	CHAIN 21..278 GDNF family receptor alpha 4.
FT	PROPEP 279..299 Removed in mature form (potential).
FT	CARBOHYD 208..208 N-linked (GLCNAc...)(potential).
FT	LIPID 278..278 GPI-anchor attached glycine (potential).
FT	VASPLIC 132..197 CARAAAGPMKGMKGISPARHPMAAQSPTGSLVPSAO RPRRLPGPPRPUPARKRGRCVPA -> PRLAFVYSCSTP APSAADGCILDQGARCIRAYAVGLV (in isoform GFralpha4a)
FT	VASPLIC 132..182 CARAAAGPMKGMKGISPARHPMAAQSPTGSLVPSAO RPRRLPGCG -> PRLAFVYSCSTPAPSADGCILDQGAR CLRAYAGLVSPQAPSPFLTTWT (in isoform GFralpha4c)
FT	VASPLIC /PrId=VSP_007224. Missing (in isoform GFralpha4c). /PrId=VSP_007225. SEQUENCE 299 AA; 31669 MW; 8443B8352FF10801 CRC64;
Query Match	54.3%; Score 767.5; DB 1; Length 299;
Best Local Similarity	62.5%; Pred. No. 4.3e-57;

Matches 157; Conservative 10; Mismatches 51; Indels 33; Gaps 3;

QY 27 GSASTEGRCYEAADACTADECCOQLRSEYVAQCLGRAGMRGPGSCVRSRCPALRRFF 86
 DB 16 GSASSVGNGRCVDAEACTADARCORLRSEYVAQCLGRAGMRGPGSCVRSRCPALRRFF 72
 QY 87 ARGPALTHALLFCGCEGPACERRRORFAPACAPSGQQLAPPSCLKPLDCESSRRCR- 145
 DB 73 ARGPALTHALLFCGCEGPACERRRORFAPACAPSGQQLAPPSCLKPLDCESSRRCR- 132
 QY 146 -----PRLFAFQASCAPAPGSRDCEPCEGRCRAY 177
 DB 133 ARAAAGPWRGWRGSLSPARPPAAQASPPGLSGLVHPSAQRRRLPAGPGRPLPARLRGP 192
 QY 178 AGL-VGTVTPTNYLDNVARSARVAPMGCEGASGNRECEAPRKLFTTRNPCLDGAIOAPDSS 236
 DB 193 RGVVAGTAVTPTNYLDNVARSARVAPMGCEGASGNRECEAPRKLFTTRNPCLDGAIOAPDSS 252
 QY 237 QPSVYLDQDQNP 247
 DB 253 WPPVLLDQDNP 263

RESULT 4

GER4_CHICK STANDARD; PRT; 431 AA.

ID 093512;
 AC 10-OCT-2003 (Rel. 42, Created)
 DT 10-OCT-2003 (Rel. 42, Last sequence update)
 DE 05-JUL-2004 (Rel. 44, Last annotation update)
 GN GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4).
 OS Gallus gallus (Chicken)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus.
 NCBI_TaxID=9031;
 RX TISSUE=Embryonic brain;
 RA MEDLINE=98313402; PubMed=9647690;
 RA Thompson J., Doxakis E., Pinon L.G.P., Strachan P., Bui-Bello A., Myatt S., Buchanan V.L., Davies A.M., Strachan P., Bui-Bello A., GFRalpha-4 a new GDNF family receptor.";
 RA Mol. Cell. Neurosci. 11:117-126(1998).
 RN IDENTIFICATION OF LIGAND.
 RX MEDLINE=98421156; PubMed=9740802;
 RA Enokido Y., de Sauvage F., Hongo J.-A., Ninkina N., Rosenthal A., Buchanan V.L., Davies A.M., Hongo J.-A., Ninkina N., Rosenthal A., GFRalpha-4 and the tyrosine kinase Ret form a functional receptor complex for persephin.";
 RA Curr. Biol. 8:1019-1022(1998).
 CC -1- FUNCTION: Receptor for persephin. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor (By similarity).
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).
 CC -1- DEVELOPMENTAL STAGE: Expressed in muscle, kidney, brain, stomach and intestine at E6. Levels increase in the brain from E6 to E18, and decrease in muscle and intestine. Levels in the kidney remain constant. From E10, expression also found in heart, lung, skin and liver. Levels in the liver increase dramatically at E18. At E18, highest expression found in kidney and brain. In the embryonic central nervous system, the spinal cord expressed the highest levels. Lower levels found in the medulla oblongata, pons, cerebellum and midbrain, and very low levels in the forebrain.
 CC -1- SIMILARITY: Belongs to the GDNF family.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

DR EMBL; AF045162; AAC36464.1; -
 DR InterPro; IPR003438; GDNF_receptor.
 DR Pfam; PF02351; GDNF; 1.
 DR PRINTS; PR01316; GDNFRECEPTOR.
 KM Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.
 FT SIGNAL 1
 FT CHAIN 1
 FT PROPEP 404 403 GDNF family receptor alpha 4.
 FT CARBOHYD 180 180 Removed in mature form (Potential).
 FT CARBOHYD 236 236 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 308 308 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 339 339 N-linked (GlcNAc...) (Potential).
 FT LIPID 403 403 GPI-anchor amidated serine (Potential).
 SQ SEQUENCE 431 AA; 47964 MW; 3EDD945D3CC4E71B CRC64;

Query Match 41.4%; Score 585.5; DB 1; Length 431;
 Best Local Similarity 47.4%; Pred. No. 1,8e-41;
 Matches 110; Conservative 37; Mismatches 72; Indels 13; Gaps 4;

QY 32 TEGNRCVBAEACTADECCOQLRSEYVAQCLGRAGMRGPGSCVRSRCPALRRFFANGPP 91
 DB 140 TQVNRCLDAARACNVDEMCORLRTEYVSFCIRRLA--RADTCNRSKCHKLRKFFDRAVP 197
 QY 92 ALTHALLFCGCEGPACERRRORFAPACAPSGQQLAPPSCLKPLDCESSRRCPRLPAF 151
 DB 198 EYTHLLFCPEEDPACERRRORFAPACAPSGQQLAPPSCLKPLDCESSRRCPRLPAF 255
 QY 152 QASCAPAPGSRDCEPCEGRCRAYAGLVGTVTPTNYLDNVARSARVAPMGCEGASGNRRE 211
 DB 256 QENCQPSLOTASGGRDRSYAACLAAYTGIGSPITPYINDNSISAPWCTCANSGRQE 315
 QY 212 ECEAPRKLFTTRNPCLDGAIOAFD-----SSQSPV--LDQNPVYNAQA 254
 DB 316 ECSESFLHFTDQVCLQNAIDPFNGYTLNATAPSISPTTOMYKQERNANRA 367

RESULT 5

098TT8 PRELIMINARY; PRT; 481 AA.

ID 098TT8
 AC 098TT8;
 DT 01-JUN-2001 (TREMBLrel. 17, Created)
 DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
 DE 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
 GN GDNF family receptor alpha-1b.
 GN Name=gfralpha1b;
 OS Brachydanio rerio (Zebrafish) (Danio rerio).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.
 NCBI_TaxID=7955;
 RN SEQUENCE FROM N.A.
 RX MEDLINE=21133398; PubMed=11237470;
 RA Shepherd I.T., Beattie C.E., Raible D.W., "Functional analysis of zebrafish GDNF.";
 RA Dev. Biol. 231:420-435(2001).
 RN SEQUENCE FROM N.A.
 RX PubMed=14660438;
 RA Shepherd I.T., Pietsch J., Elworthy S., Kelch R.N., Raible D.W., "Roles for GFR(alpha)1 receptors in zebrafish enteric nervous system development.";
 RA Development 131:241-249(2004).
 RT EMBL; AY436321; AK11261.2; -
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR003438; GDNF_receptor.
 DR Pfam; PF02351; GDNF; 1.
 DR PRINTS; PR01316; GDNFRECEPTOR.
 KW Receptor.

SEQUENCE 481 AA; 53639 MW; 478917653049CE23 CRC64;

Query Match 33.7%; Score 476.5; DB 2; Length 481;

Best Local Similarity 39.9%; Pred. No. 3.6e-32; Matches 93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;

QY 27 GSASTEGNRCVAAEACTADEOCQOLRSEVYVACLRAGWGRPGSCVSRRCRRALRRF 86
 DB 152 GEAAFTKDNKCNLAQAACNLNDCKKRYRLSYIPCSIRVS--TTEVCNKRCKKALRQPF 209
 QY 87 AAGPPALTTALLFCGC--EGPACARRRQTFAPACAFSGPOLAPPSCLKPLDRCSRR 143
 DB 210 DKVPFGHSGMLFCSPGSDHSACSRRRQTIYPACSYEDKE--KENCISLQASCKTNYI 267
 QY 144 CRPRLEFAFQASCAPAGSRDGCPEEGPRCLRAVAGLVGTVPNTYLDNVSAVAFWCCG 203
 DB 268 CSRSLADFLTNCPPEARISIGCLKENYADCLLAVSGLIGVTMPNLYRPAIGISVSPWCCD 327
 QY 204 EASGNRECEAFRKLFTNPCLDGAIOAFDS-----OPSVLQDDQWNPY 248
 DB 328 SNSGNKACDCDKTEFTTNNRCLRNAIOAFGNGTDVGWQPPPISTPADPY 380

RESULT 6

AAK11261 PRELIMINARY; PRT; 481 AA.

AC AAK11261; 02-MAR-2004 (TREMBlrel. 27, Created)
 DT 02-MAR-2004 (TREMBlrel. 27, Last sequence update)
 DT 02-MAR-2004 (TREMBlrel. 27, Last annotation update)
 DE GDNF family receptor alpha-1b.
 GN GPRALPHA1B
 OS Brachydanio rerio (zebrafish) (Danio rerio).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
 OC Cyprinidae; Danio.
 OK NCBI_TaxId=7955;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21135398; PubMed=11337470;
 RA Shepherd I.T., Beattie C.E., Raible D.W.;
 RT "Functional analysis of zebrafish GDNF.";
 RT Dev. Biol. 231:420-435 (2001).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX PubMed=14660438;
 RA Shepherd I.T., Pietesch J., Elworthy S., Keish R.N., Raible D.W.;
 RT "Roles for GPR(alpha)1 receptors in zebrafish enteric nervous system development.";
 RT development. 131:241-249 (2004).
 DR EMBL; AY436321; AAK11261.2; -.
 KW Receptor.
 SQ SEQUENCE 481 AA; 53639 MW; 478917653049CE23 CRC64;

Query Match 33.7%; Score 476.5; DB 2; Length 481;
 Best Local Similarity 39.9%; Pred. No. 3.6e-32; Matches 93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;
 QY 27 GSASTEGNRCVAAEACTADEOCQOLRSEVYVACLRAGWGRPGSCVSRRCRRALRRF 86
 DB 152 GEAAFTKDNKCNLAQAACNLNDCKKRYRLSYIPCSIRVS--TTEVCNKRCKKALRQPF 209
 QY 87 AAGPPALTTALLFCGC--EGPACARRRQTFAPACAFSGPOLAPPSCLKPLDRCSRR 143
 DB 210 DKVPFGHSGMLFCSPGSDHSACSRRRQTIYPACSYEDKE--KENCISLQASCKTNYI 267
 QY 144 CRPRLEFAFQASCAPAGSRDGCPEEGPRCLRAVAGLVGTVPNTYLDNVSAVAFWCCG 203
 DB 268 CSRSLADFLTNCPPEARISIGCLKENYADCLLAVSGLIGVTMPNLYRPAIGISVSPWCCD 327
 QY 204 EASGNRECEAFRKLFTNPCLDGAIOAFDS-----OPSVLQDDQWNPY 248
 DB 328 SNSGNKACDCDKTEFTTNNRCLRNAIOAFGNGTDVGWQPPPISTPADPY 380

RESULT 7

Q922A2 PRELIMINARY; PRT; 330 AA.

AC Q922A2; 01-MAY-1999 (TREMBlrel. 10, Created)
 DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)
 DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)
 DE Glial cell line derived neurotrophic factor family receptor alpha 2c.
 GN Name=Gfra2;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OK NCBI_TaxId=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wong Y.W., Too H.P.;
 RT "Identification of mammalian Gfra-2 splice isoforms.";
 RT Neuroreport 9:0-0(1998).
 RL EMBL; AF079108; AAC82465.1; -.
 DR MGD; MGI:1195462; Gfra2.
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR003438; GDNF_receptor.
 DR InterPro; IPR003504; GDNF_receptor2.
 DR Pfam; PF02351; GDNF_1.
 DR PRINTS; PRO1318; GDNFRALPHA2.
 DR PRINTS; PRO1316; GDNFRECEPTOR.
 KW Receptor.
 SQ SEQUENCE 330 AA; 36506 MW; ADA14BF4C277594 CRC64;

Query Match 33.3%; Score 471; DB 2; Length 330;
 Best Local Similarity 42.5%; Pred. No. 7.3e-32; Matches 91; Conservative 31; Mismatches 86; Indels 6; Gaps 3;

QY 22 LCGQSGASTEGNRCVAAEACTADEOCQOLRSEVYVACLRAGWGRPGSCVSRRCRR 81
 DB 13 LGTGADPVVASNSNHLDAKACNLNDCKKRSYSISCNBIS--PTERCNRRCKHKA 70
 QY 82 LRRFARPPALTTALLFCGCAGPACARRRQTFAPACAFSGPOLAPPSCLKPLDRCSRR 141
 DB 71 LRQFPDRVSEYTRNLFCSCQDQACARRRQTIIPSCYEDKE--KPKCLDRSLSCRND 128
 QY 142 RRCRPRLEFAFQASCAPAGSRDGCPEEGPRCLRAVAGLVGTVPNTYLDN--VSARVAP 199
 DB 129 HICRSRLADFPANCRASVYRTISCPADNYQACISYAGMIGPDMPTNYVDSNPTGIIVSP 188
 QY 200 WGCGRASGNRECEAFRKLFTNPCLDGAIOAF 233
 DB 189 WCNCRSGNMBEBCXFLMDFTENPCLRNAIOAF 222

RESULT 8

Q922A3 PRELIMINARY; PRT; 358 AA.

AC Q922A3; 01-MAY-1999 (TREMBlrel. 10, Created)
 DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)
 DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)
 DE Glial cell line derived neurotrophic factor family receptor alpha 2b.
 GN Name=Gfra2;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OK NCBI_TaxId=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wong Y.W., Too H.P.;
 RT "Identification of mammalian Gfra-2 splice isoforms.";
 RT Neuroreport 9:0-0(1998).
 RL EMBL; AF079107; AAC82464.1; -.
 DR

```

DR MGD; MGI:1195462; Gfira2.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003438; GDNF_receptor.
DR InterPro; IPR003504; GDNF_receptor2.
DR Pfam; PF02351; GDNF.1.
DR PRINTS; PRO1318; GDNFRALPHA2.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR Receptor.
SQ SEQUENCE 358 AA; 39700 MW; F440CE3B1F629225 CRC64;

Query Match 33.2%; Score 469; DB 2; Length 358;
Best Local Similarity 43.4%; Pred. No. 1.2e-31;
Matches 89; Conservative 31; Mismatches 79; Indels 6; Gaps 3;

QY 31 STEGNVCVEAEACTADBOCOQLRSEYVAQCLGRAGRGSGCVSRRCRRALRFFAR 90
DB 50 SAESNCHLDAAKACNLDNCKLRSSYSICNREIS--PTERCNRKCKHAKLRQFDRVP 107
QY 91 PALTHALFPCGCEGPAEARRRQTFAPACAFSGPOLAPSPCLKPLDRCSRRRCRPLA 150
DB 108 SEYTYMFLFCSCQDOQCAERRRQTIIPSCSYEDKE--KXNCLDLRSLCTDHLCRSLAD 165
QY 151 FQASCAPAGSRDGCPEBGGPRCLRAYAGLVGTVTNTYLDN--VSARVAPMCGCEASGN 208
DB 166 FHANCRASRYRTITSCPADNYOACLSYAGMIGFDMTPNYVDSNPTGIIVSPMNCRCGSGN 225
QY 209 RRECEAFRLFTFRNPCLDGAIOAF 233
DB 226 MEBCCKFLKDTFENPCLRNALIOAF 250

RESULT 9
QY 9792X9 PRELIMINARY; PRT; 444 AA.
AC 0792X9;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DI GDNF_receptor-beta (Fragment).
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC NCBI_TaxId=10116;
RN 11
RP SEQUENCE FROM N.A.
RC TISSUE=Hippocampus;
RX MEDLINE=97402208; PubMed=9259272;
RA Suvanto P., Marttolaara K., Lindahl M., Arumae U., Moshnyakov M.,
RA Horelli-Kuitunen N., Aitakainen M.S., Palotie A., Sariola H.,
RA Saarma M.;
RT "Cloning, mRNA distribution and chromosomal localisation of the gene
RT for glial cell line-derived neurotrophic factor receptor beta, a
RT homologue to GDNF-alpha."
RL Hum. Mol. Genet. 6:1267-1273 (1997).
DR EMBL; AF003825; AAD09310.1;
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003438; GDNF_receptor.
DR InterPro; IPR003504; GDNF_receptor2.
DR Pfam; PF02351; GDNF.1.
DR PRINTS; PRO1318; GDNFRALPHA2.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR Receptor.
KW NON_TER.
SQ SEQUENCE 444 AA; 49578 MW; A548644EDB36D5F3 CRC64;

Query Match 33.2%; Score 469; DB 2; Length 444;
Best Local Similarity 43.0%; Pred. No. 1.5e-31;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASSTEGNRCVEAEACTADBOCOQLRSEYVAQCLGRAGRGSGCVSRRCRRALRFFAR 88
DB 153 AVSTKSNHCLDAKACNLDNCKLRSSYSICNREIS--PTERCNRKCKHAKLRQFDR 210

```

```

QY 89 GPPALTHALFPCGCEGPAEARRRQTFAPACAFSGPOLAPSPCLKPLDRCSRRRCRPL 148
DB 211 VSEYTYMFLFCSCQDOQCAERRRQTIIPSCSYEDKE--KXNCLDLRSLCTDHLCRSL 268
QY 149 FQASCAPAGSRDGCPEBGGPRCLRAYAGLVGTVTNTYLDN--VSARVAPMCGCEAS 206
DB 269 ADFHANCRASRYRTITSCPADNYOACLSYAGMIGFDMTPNYVDSNPTGIIVSPMNCRCGS 328
QY 207 GNRRECEAFRLFTFRNPCLDGAIOAF 233
DB 329 GNMEECKFLKDTFENPCLRNALIOAF 355

RESULT 10
QY 035977 PRELIMINARY; PRT; 464 AA.
AC 035977;
DT 01-JAN-1998 (TrEMBLrel. 05, Created)
DT 01-JAN-1998 (TrEMBLrel. 05, Last sequence update)
DE 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DI Glial cell line-derived neurotrophic factor receptor-beta (RET ligand
DI 2).
OS Name=GDNF-beta; Synonyms=RET12;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC NCBI_TaxId=10116;
RN 11
RP SEQUENCE FROM N.A.
RX MEDLINE=98271460; PubMed=9608533;
RA Trump M., Raynoschek C., Belluardo N., Ibanez C.F.;
RT "Multiple GPI-anchored receptors control GDNF-dependent and
RT independent activation of the c-Ret receptor tyrosine kinase."
RL Mol. Cell. Neurosci. 11:47-63 (1998).
RN 12
RP SEQUENCE FROM N.A.
RC TISSUE=Brain/Kidney;
RX MEDLINE=97322356; PubMed=9177201;
RA Santicola M., Hession C.A., Worley D.S., Carmillo P., Ehrenfels C.,
RA Walus L., Robinson S., Jaworski G., Wei H., Tizard R., Whitty A.,
RA Pepinsky R.B., Cate R.L.;
RT "Glial cell line-derived neurotrophic factor-dependent RET activation
RT can be mediated by two different cell-surface accessory proteins."
RL Proc. Natl. Acad. Sci. U.S.A. 94:6238-6243 (1997).
DR EMBL; AF005226; AAB62247.1;
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003438; GDNF_receptor.
DR InterPro; IPR003504; GDNF_receptor2.
DR Pfam; PF02351; GDNF.1.
DR PRINTS; PRO1318; GDNFRALPHA2.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR Receptor.
KW RECEPTOR.
SQ SEQUENCE 464 AA; 51668 MW; 81168301BE50D6CC CRC64;

Query Match 33.2%; Score 469; DB 2; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.5e-31;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASSTEGNRCVEAEACTADBOCOQLRSEYVAQCLGRAGRGSGCVSRRCRRALRFFAR 88
DB 153 AVSTKSNHCLDAKACNLDNCKLRSSYSICNREIS--PTERCNRKCKHAKLRQFDR 210
QY 89 GPPALTHALFPCGCEGPAEARRRQTFAPACAFSGPOLAPSPCLKPLDRCSRRRCRPL 148
DB 211 VSEYTYMFLFCSCQDOQCAERRRQTIIPSCSYEDKE--KXNCLDLRSLCTDHLCRSL 268
QY 149 FQASCAPAGSRDGCPEBGGPRCLRAYAGLVGTVTNTYLDN--VSARVAPMCGCEAS 206
DB 269 ADFHANCRASRYRTITSCPADNYOACLSYAGMIGFDMTPNYVDSNPTGIIVSPMNCRCGS 328
QY 207 GNRRECEAFRLFTFRNPCLDGAIOAF 233

```


Db 329 GNMEECEKFLRDPFTENPCLRNALIOAF 355

RESULT 11

ID GFR2_MOUSE STANDARD; PRT; 463 AA.

AC 008432;

DT 01-NOV-1997 (Rel. 35, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE GDNF family receptor alpha 2 precursor (GFR-alpha 2) (Neurturin receptor alpha) (NTRN-alpha) (NTRN-alpha) (TGF-beta related neurotrophic factor receptor 2) (GDNF receptor beta) (GDNFR-beta).

GN Name=Gfra2; Synonyms=gdnfrb, Trnr2;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

[1]

RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).

RX MEDLINE=97325791; PubMed=9182803;

RA Balon R.H., Tansey M.G., Golden J.P., Heuckeroth R.O., Reck C.L., Zimonjic D.B., Popescu N.C., Johnson E.M. Jr., Milbrandt J.;

RA "Trnr2, a novel receptor that mediates neurturin and GDNF signaling through Ret.";

RT Neuron 18:793-802(1997).

CC -1- FUNCTION: Receptor for neurturin. Mediates the NRTN-induced autophosphorylation and activation of the RET tyrosine kinase receptor.

CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).

CC -1- ALTERNATIVE PRODUCTS:

CC Event=Alternative splicing; Named isoforms=2;

CC Name=1; Synonyms=Long;

CC IsoId=O08842-1; Sequence=Displayed;

CC Name=2; Synonyms=Short;

CC IsoId=O08842-2; Sequence=VSP_001662;

CC -1- TISSUE SPECIFICITY: Neurons of the superior cervical and dorsal root ganglia, and adult brain and testis. Low level in the spleen and in the adrenal gland.

CC -1- SIMILARITY: Belongs to the GDNFR family.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - CC the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.1sb-sib.ch/announce/> or send an email to license@1sb-sib.ch).

CC -----

DR EMBL; AF002701; AAC53548.1; -.

DR MGD; MGI:1195462; Gfra2.

DR InterPro: IPR003438; GDNF_receptor.

DR Pfam: PF02351; GDNF_1

DR PRINTS; PR01316; GDNFRECEPTOR.

DR KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.

KW SIGNAL

FT CHAIN 1 21 Potential.

FT FT 22 443 GDNF family receptor alpha 2.

FT PROPEP 444 463 Removed in mature form (Potential).

FT CARBOHYD 52 52 N-linked (GlcNAc...) (Potential).

FT CARBOHYD 357 357 N-linked (GlcNAc...) (Potential).

FT CARBOHYD 413 413 N-linked (GlcNAc...) (Potential).

FT LIPID 443 443 GPI-anchor amidated serine (Potential).

FT VARSPLIC 14 14 Missing (in isoform 2).

FT FT /Ptm=VSP_001662.

SO SEQUENCE 463 AA; 51598 MW; 4FB495F858C61F78 CRC64;

Query Match 32.9%; Score 465; DB 1; Length 463;

Best Local Similarity 42.9%; Pred. No. 3.3e-31;

Matches 88; Conservative 32; Mismatches 79; Indels 6; Gaps 3;

QY 31 STEGNRCVFAAEACTADEOCQQLRSEYVAQCLCRAGRGSGCVSRRCRAALRRPARCP 90

DB 155 SAKSNHCIDPAAKACNINDNCKLRSSYSISICNNEIS--PTERCNRKCHKLQFPDRVP 212

QY 91 PALTHALFCGCEGPACAEERRRQTFAPACAFSGPOLAPSPCLKPLDRCCSRRCRPLFA 150

DB 213 SEYTYMLFCSCODQCAERRRQTIIPSCSYRKE--KRNCLDRSLCRTDHLCRSLAD 270

QY 151 PQASCAPAPGSRDCEEGPRCLRAYAGLVGTVPNTLND--VSARVAPWCCEASGN 208

DB 271 FHANCRASRTITSCADNVQACLSGYAGWIGFDMTPNYDSNPTGIWVSPMNCGSGSN 330

QY 209 RRECEAPKFLPRNPNCLDGLIOAF 233

DB 331 MEEBCEKFLRDPFTENPCLRNALIOAF 355

RESULT 12

ID Q920Y3 PRELIMINARY; PRT; 463 AA.

AC Q920Y3;

DT 01-DEC-2001 (TrEMBLrel. 19, Created)

DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

DE Glial cell line derived neurotrophic factor family receptor alpha 2.

GN Name=Gfra2;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

[1]

RP SEQUENCE FROM N.A.

RX STRAIN=C57BL;

RX MEDLINE=22712886; PubMed=12829325;

RA Too H.P.;

RT "Real time PCR quantification of GFRalpha-2 alternatively spliced isoforms in murine brain and peripheral tissues.";

RT Brain Res. Mol. Brain Res. 114:146-153(2003).

RP [2]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL;

RA Wong Y.W., Too H.P.;

RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF398416; AAK97483.1; -.

DR EMBL; AF398411; AAK97483.1; JOINED.

DR EMBL; AF398412; AAK97483.1; JOINED.

DR EMBL; AF398414; AAK97483.1; JOINED.

DR EMBL; AF398415; AAK97483.1; JOINED.

DR EMBL; AF398413; AAK97483.1; JOINED.

DR GO; GO:0004872; F:receptor activity; IEA.

DR InterPro: IPR003438; GDNF_receptor.

DR InterPro: IPR003504; GDNF_receptor2.

DR Pfam: PF02351; GDNF_1.

DR PRINTS; PR01316; GDNFRECEPTOR.

DR PRINTS; PR01316; GDNFRECEPTOR.

DR KW Receptor.

SO SEQUENCE 463 AA; 51582 MW; 42FAA1BF5975E2C CRC64;

Query Match 32.9%; Score 465; DB 2; Length 463;

Best Local Similarity 42.9%; Pred. No. 3.3e-31;

Matches 88; Conservative 32; Mismatches 79; Indels 6; Gaps 3;

QY 31 STEGNRCVFAAEACTADEOCQQLRSEYVAQCLCRAGRGSGCVSRRCRAALRRPARCP 90

DB 155 SAKSNHCIDPAAKACNINDNCKLRSSYSISICNNEIS--PTERCNRKCHKLQFPDRVP 212

QY 91 PALTHALFCGCEGPACAEERRRQTFAPACAFSGPOLAPSPCLKPLDRCCSRRCRPLFA 150

DB 213 SEYTYMLFCSCODQCAERRRQTIIPSCSYRKE--KRNCLDRSLCRTDHLCRSLAD 270

QY 151 PQASCAPAPGSRDCEEGPRCLRAYAGLVGTVPNTLND--VSARVAPWCCEASGN 208

DB 271 FHANCRASRTITSCADNVQACLSGYAGWIGFDMTPNYDSNPTGIWVSPMNCGSGSN 330

QY 209 RRECEAPKFLPRNPNCLDGLIOAF 233

DB 331 MEEBCEKFLRDPFTENPCLRNALIOAF 355

Db 271 FHANCRASVYTTTSCPADNVQACGSGTAKMTGPMNTNYVDSNPTGTIVSPKCNCRGSGN 330
 QY 209 RRECEAFKLTFTNPLCLDGAIOAF 233
 Db 331 MEECEKFLNDFTENPCLRNAIOAF 355

RESULT 13
 GFR1_HUMAN STANDARD; PRT; 465 AA.
 ID GFR1_HUMAN STANDARD; PRT; 465 AA.
 AC P56159; O15507; O43912;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE GDNF family receptor alpha 1 precursor (GFR-alpha 1) (GDNF receptor alpha) (GDNFR-alpha) (TGF-beta related neurotrophic factor receptor 1) (RET ligand 1).
 DE Name=GFR1; Synonyms=GDNFRA, TRNR1, RETL1;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 NC NCB1_TaxID=9606;
 RX [1]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Substantia nigra;
 RX MEDLINE=96270513; PubMed=8674117;
 RA Jang S., Wen D., Yu Y., Holst P.L., Luo Y., Fang M., Tamir R., Antonio L., Hu Z., Cupples R., Louis J.-C., Hu S., Altrock B.W., Fox G.M., Hu Z., Cupples R., Louis J.-C., Hu S., Altrock B.W., "GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.", Cell 85:1113-1124(1996).
 RL [2]
 RN SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Kidney;
 RX MEDLINE=9732356; PubMed=9177201;
 RA Sandoia M., Hession C.A., Worley D.S., Carmillo P., Ehrenfels C., Walus L., Robinson S., Jaworski G., Wei H., Tizard R., Whitty A., Pepinsky R.B., Cate R.L., "Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins.", Proc. Natl. Acad. Sci. U.S.A. 94:6238-6243(1997).
 RL [3]
 RN SEQUENCE FROM N.A. (ISOFORM 1), AND VARIANTS ASN-85 AND ALA-366.
 RX MEDLINE=98207251; PubMed=9545641; DOI=10.1006/geno.1997.5191.
 RA Angrist M., Jang S., Bolk S., Bentley K., Mallasamy S., Halushka M., Fox G.M., Chakravarti A., "Human GFR1: cloning, mapping, genomic structure, and evaluation as a candidate gene for Hirschsprung disease susceptibility.", Genomics 48:354-362(1998).
 RL [4]
 RN SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Thyroid carcinoma;
 RX MEDLINE=98260874; PubMed=9600247;
 RA Shefelbine S.E., Khorana S., Schultz P.N., Huang E., Thobe N., Hu Z.J., Fox G.M., Jang S., Cote G.J., Gargel R.F., "Mutational analysis of the GDNF/RET-GDNFR-alpha signaling complex in a kindred with vesicoureteral reflux.", Hum. Genet. 102:474-478(1998).
 RL [5]
 RN SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Substantia nigra;
 RA Hishiki T., Kondoh K., Ichimiya S., Nimura Y., Seki N., Ozaki T., Sakiyama S., Takahashi H., Ohnuma N., Tanabe M., Fujimura S., Nakagawa A., "GDNF-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-ret and GDNFR-alpha.", Submitted (Oct-1997) to the EMBL/GenBank/DBJ databases.
 RL [6]
 RN SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Eye;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Pelngold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Scheffer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ueda T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loggellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
 RA Villalón D.K., Mizny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kerteman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butlerfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.",
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [7]
 RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
 RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
 RA Hillman R.T., Green R.E., Brenner S.E.,
 RA "An unappreciated role for RNA surveillance.",
 RL Genome Biol. 5:RESEARCH008.1-RESEARCH008.16(2004).
 RN [8]
 RP VARIANTS ALA-366 AND ARG-371.
 RX PubMed=1456559; DOI=10.1007/s00439-003-1036-z;
 RA Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
 RA Otake S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
 RA Nakamura T., Hayasaka K.,
 RT "Molecular analysis of congenital central hypoventilation syndrome.",
 RL Hum. Genet. 114:22-26(2003).
 CC -1- FUNCTION: Receptor for GDNF. Mediates the GDNF-induced
 CC autophosphorylation and activation of the RET receptor (By
 CC similarity).
 CC -1- SUBUNIT: 2 molecules of GDNFR-alpha are thought to form a complex
 CC with the disulfide-linked GDNF dimer and with 2 molecules of RET
 CC (By similarity).
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By
 CC similarity).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Name=1; Isoform=Displayed;
 CC Name=2; Isoform=Displayed;
 CC IsoID=P56159-2; Sequence=VSP 001660;
 CC Note=May be produced at very low levels due to a premature stop
 CC codon in the mRNA, leading to nonsense-mediated mRNA decay;
 CC -1- SIMILARITY: Belongs to the GDNFR family.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; U97144; AAC51646.1; -;
 CC EMBL; AF038420; AAC39693.1; -;
 CC EMBL; AF038411; AAC39693.1; JOINED.
 CC EMBL; AF038412; AAC39693.1; JOINED.
 CC EMBL; AF038413; AAC39693.1; JOINED.
 CC EMBL; AF038414; AAC39693.1; JOINED.
 CC EMBL; AF038415; AAC39693.1; JOINED.
 CC EMBL; AF038416; AAC39693.1; JOINED.
 CC EMBL; AF038417; AAC39693.1; JOINED.
 CC EMBL; AF038418; AAC39693.1; JOINED.
 CC EMBL; AF038419; AAC39693.1; JOINED.
 CC EMBL; AF038421; AAC39692.1; -;
 CC EMBL; AF042080; AAB97371.1; -;


```

DR EMBL; AF058999; AAC14431.1; -.
DR EMBL; AF058990; AAC14431.1; JOINED.
DR EMBL; AF058991; AAC14431.1; JOINED.
DR EMBL; AF058992; AAC14431.1; JOINED.
DR EMBL; AF058993; AAC14431.1; JOINED.
DR EMBL; AF058994; AAC14431.1; JOINED.
DR EMBL; AF058995; AAC14431.1; JOINED.
DR EMBL; AF058996; AAC14431.1; JOINED.
DR EMBL; AF058997; AAC14431.1; JOINED.
DR EMBL; AF058998; AAC14431.1; JOINED.
DR EMBL; U95847; AAB7181.1; -.
DR EMBL; BC014962; AAL14962.1; -.
DR Gene; HGNC:4243; GFRAL.
DR MIM; 601496; -.
DR GO; GO:0019898; C:extrinsic to membrane; NAS.
DR GO; GO:0004872; F:receptor activity; NAS.
DR GO; GO:0007166; P:cell surface receptor linked signal transdu. .; NAS.
DR InterPro; IPR003438; GDNF_receptor.
DR Pfam; PF02351; GDNF; 1.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
KW Polymorphism; Receptor; Signal.
FT SIGNAL 1 24
FT CHAIN 25 429 GDNF family receptor alpha 1.
FT PROPEP 430 465 Removed in mature form (Potential).
FT DOMAIN 362 369 Poly-Thr.
FT CARBOHYD 359 369 N-linked (GlcNAc. .) (Potential).
FT CARBOHYD 347 347 N-linked (GlcNAc. .) (Potential).
FT CARBOHYD 406 406 N-linked (GlcNAc. .) (Potential).
FT LIPID 429 429 GPI-anchor amidated serine (Potential).
FT VARSPLIC 140 144 Missing (in isoform 2).
FT VARIANT 85 85 /FridaVSP_001660.
FT Y->N (in ddsnp:8192662).
FT VARIANT 366 366 /FridaVAR_012488.
FT T->A (in ddsnp:2072276).
FT VARIANT 371 371 /FridaVAR_012489.
FT L->R (may be involved in congenital
FT central hypoventilation syndrome).
FT CONFLICT 245 245 /FridaVAR_018261.
FT CONFLICT 358 358 Missing (in Ref. 1).
FT SEQUENCE 465 AA; 51455 MW; 91A550D06A677BD CRC64;
SQ
Query Match 32.8%; Score 465; DB 1; Length 465;
Best Local Similarity 41.9%; Pred. No. 3, 3e-31;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;
QY 33 EGNRCVEAAEACTADECCOQLRSEYVAOCLGRAGMRGPGSCVSRGRRLRRFPARGPPA 92
DB 150 KGNNCDDAAKAKCNLDICCKYRSAYITPCTSV---SNDVCNRKCKHKLROFFDKVPAPK 206
QY 93 LTHALLFCGCGPACAEERRRQTFAPACAFSGPQLAPSPCLKPLDRGERSRRCRPLPARQ 152
DB 207 HSYGMFLFCGCRDIACTERRRQTIIVPCSYE--ERKPNCLINDQCKTYICGSRADLF 264
QY 153 AACCAPPGSRDGCPEEGGPRCLRAYGLVGTVTPTVYLDNVSARVAPMGCCGASGRREE 212
DB 265 TNCQPSRSRSVSGCLKKNYADCLLAYSGLTGVTWPTVYIDSSLSVAPWCDSCNSGNDLEE 324
QY 213 CEAFRLFTFRNPCLDGAIOAFDSSQPSVQDDONP 247
DB 325 CLKFLNFPKDNCTCLKAIOAFGNGSDVTV---WQP 356
RESULT 14
ID 0725C2 PRELIMINARY; PRT; 331 AA.
AC 0725C2;
DT 01-OCT-2003 (TEMBLrel. 25, Created)
DT 01-OCT-2003 (TEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TEMBLrel. 26, Last annotation update)
DE Glial cell 11ne-derived neurotrophic factor family receptor
alpha2c.

```

```

OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Yoong L.F., Too H.P.;
RU Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY326396; AAB88378.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003438; GDNF_receptor.
DR Pfam; PF02351; GDNF; 1.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR KW Receptor.
SQ SEQUENCE 331 AA; 36470 MW; 10ECEA5492E2333C CRC64;
Query Match 32.8%; Score 464; DB 2; Length 331;
Best Local Similarity 38.7%; Pred. No. 2, 9e-31;
Matches 92; Conservative 38; Mismatches 102; Indels 6; Gaps 3;
QY 22 LGCGRGSASTEGNRCVEAAEACTADECCOQLRSEYVAOCLGRAGMRGPGSCVSRGRRA 81
DB 13 LGTGADPVVSAXSNHCLDAKACNLNDCKKURSSYISICNBEIS--PTERCNRKCHXA 70
QY 82 LRFPARGPPLTHALLFCGCGPACAEERRRQTFAPACAFSGPQLAPSPCLKPLDRGERS 141
DB 71 LRQFFDVRVSEYTRKMLFSCQDQACAEERRRQTIIVPCSYEDKE--KPNCLDRGVCRTD 128
QY 142 RRCRPLFAFQASCAPAPSGRDCPEEGGPRCLRAYGLVGTVTPTVYLDN--VSARVAP 199
DB 129 HICRSRLADPFHANCRASTYGTIVTSCPADNYQACLGSGVAGMIGPDMFTNYDSSPTGIVS 188
QY 200 WCCGCEASGRREBECEAFRLFTFRNPCLDGAIOAFDSSQPSVLDONPYNQAGQAYE 257
DB 189 WCCSRGSGMBEBCETFLRDFTENPCLRNAIOAFGNGTDVNVSPKPSFOATQAPRVE 246
RESULT 15
ID 035252 PRELIMINARY; PRT; 463 AA.
AC 035252;
DT 01-JAN-1998 (TEMBLrel. 05, Created)
DT 01-JAN-1998 (TEMBLrel. 05, Last sequence update)
DT 01-JUN-2003 (TEMBLrel. 24, Last annotation update)
DE GDNF receptor beta.
GN Name=Glr1; Synonyms=GDNFR-beta;
OC Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=98252741; PubMed=9592044;
RA Dey B.K., Wong Y.W., Too H.P.;
RT "Cloning of a novel murine isoform of the glial cell 11ne-derived
RT neurotrophic factor receptor."
RT Neuroreport 9:37-42(1998).
DR EMBL; AF015172; AAB86600.1; -.
DR MGD; MG1:1100842; Gfral.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003438; GDNF_receptor.
DR InterPro; IPR003503; GDNF_receptor.
DR Pfam; PF02351; GDNF; 1.
DR PRINTS; PRO1317; GDNFRALPHA1.
DR PRINTS; PRO1316; GDNFRECEPTOR.
SQ SEQUENCE 463 AA; 51134 MW; EAF2A1522622C037 CRC64;
Query Match 32.8%; Score 464; DB 2; Length 463;
Best Local Similarity 41.2%; Pred. No. 4e-31;
Matches 89; Conservative 32; Mismatches 87; Indels 8; Gaps 3;
QY 32 TEGNRCVEAAEACTADECCOQLRSEYVAOCLGRAGMRGPGSCVSRGRRLRRFPARGPP 91

```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OW protein - protein search, using SW model

Run on: January 26, 2005, 13:09:51 : Search time 40 Seconds

(without alignments)
427.751 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413
Sequence: 1 MSGAYLRLNERPGQAVLM.....SVLQDPWNYQNAQAKVEA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-Processing: Minimum Match 0%

Listing first 45 summaries

Database :

Issued Patents AA:*
1: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
2: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*
3: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
4: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*
5: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
6: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	515	36.4	132	3	US-09-724-864-65
2	469	33.2	445	4	US-08-861-990-11
3	469	33.2	464	3	US-08-957-063-6
4	469	33.2	464	3	US-09-487-685-6
5	469	33.2	464	3	US-08-802-805D-6
6	469	33.2	464	4	US-08-861-990-2
7	469	33.2	464	4	US-09-388-316C-6
8	469	33.2	664	3	US-09-487-685-18
9	469	33.2	664	3	US-08-802-805D-18
10	469	33.2	664	4	US-09-388-316C-18
11	469	33.2	664	4	US-09-187-906-9
12	469	33.2	460	4	US-08-802-805D-22
13	469	33.2	460	4	US-09-187-906-11
14	469	33.2	460	4	US-08-837-199A-10
15	469	33.2	463	4	US-08-837-199A-12
16	469	33.2	463	4	US-08-837-199A-2
17	469	33.2	465	4	US-08-837-199A-2
18	469	33.2	465	4	US-08-837-199A-6
19	469	33.2	465	4	US-08-861-990-8
20	469	33.2	465	4	US-09-388-316C-22
21	469	33.2	464	3	US-08-957-063-3
22	469	33.2	464	3	US-09-487-685-3
23	469	33.2	464	3	US-08-802-805D-3
24	469	33.2	464	4	US-09-187-906-13
25	469	33.2	464	4	US-08-861-990-9
26	469	33.2	464	4	US-09-388-316C-3
27	469	33.2	468	3	US-08-802-805D-21

28	462	32.7	468	4	US-08-837-199A-4	Sequence 4, Appl
29	462	32.7	468	4	US-08-860-370-2	Sequence 2, Appl
30	462	32.7	468	4	US-09-187-906-2	Sequence 2, Appl
31	462	32.7	468	4	US-08-861-990-1	Sequence 1, Appl
32	462	32.7	468	4	US-09-388-316C-21	Sequence 21, Appl
33	462	32.7	664	3	US-08-957-063-16	Sequence 16, Appl
34	462	32.7	664	3	US-09-487-685-16	Sequence 16, Appl
35	462	32.7	664	3	US-08-802-805D-16	Sequence 16, Appl
36	462	32.7	664	4	US-09-388-316C-16	Sequence 16, Appl
37	399	28.2	232	4	US-08-837-199A-14	Sequence 14, Appl
38	399	28.2	294	4	US-08-837-199A-16	Sequence 16, Appl
39	364.5	25.8	346	4	US-09-187-906-15	Sequence 15, Appl
40	364.5	25.8	397	3	US-09-487-685-15	Sequence 15, Appl
41	364.5	25.8	397	4	US-09-187-906-17	Sequence 17, Appl
42	361	25.5	315	4	US-09-187-906-19	Sequence 19, Appl
43	361	25.5	400	3	US-09-528-63	Sequence 63, Appl
44	361	25.5	400	4	US-09-187-906-21	Sequence 21, Appl
45	255.5	18.1	219	4	US-08-837-199A-18	Sequence 18, Appl

ALIGNMENTS

```

RESULT 1
US-09-724-864-65
; Sequence 65, Application US/09724864
; Patent No. 6380362
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Marison, James G.
; TITLE OF INVENTION: Polynucleotides, polypeptides expressed
; FILE REFERENCE: 11000.1050U1
; CURRENT APPLICATION NUMBER: US/09/724,864
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: U.S. No. 6380362 60/171,678
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 65
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Mouse
US-09-724-864-65

Query Match          36.4%; Score 515; DB 3; Length 132;
Best Local Similarity 94.0%; Pred. No. 2, 4e-40;
Matches 94; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 145 RRLPAFQASCAPAGSRDCEBEGPRLCAIYAGIVGTVPNTLDNVSARVAPWCGCE 204
    |||||
DB 9 RRLPAFQASCAPAGSRDCEBEGPRLCAIYAGIVGTVPNTLDNVSARVAPWCGCA 68
    |||||

QY 205 ASGNRRECEAPRKLFTNRPCLDGAIOAFDSQPSVLDQD 244
    |||||
DB 69 ASGNRRECEAPRKLFTNRPCLDGAIOAFDSQPSVLDQD 108
    |||||

RESULT 2
US-08-861-990-11
; Sequence 11, Application US/08861990
; Patent No. 6696259
; GENERAL INFORMATION:
; APPLICANT: Ibanez, Carlos F.
; APPLICANT: Arumae, Urmas
; APPLICANT: Sariola, Hannu
; APPLICANT: Suvanto, Petro
; APPLICANT: Trupp, Miles
; APPLICANT: Saarma, Mart
; TITLE OF INVENTION: Glial Cell Line-Derived Neurotrophic Factor Receptors
; FILE REFERENCE: CEPH0418
; CURRENT APPLICATION NUMBER: US/08/861,990
; CURRENT FILING DATE: 1997-05-22

```


TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-487-685-6

Query Match 33.2%; Score 469; DB 3; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASTEGNRCVEAAEACTADECCQQLRSEVVAOCLGAGRGSGSCVRSRCRRLRRFPAR 88
DB 153 AVSTSNHCLDAKACNLNDNCKLRSSYISICNREIS--PTERCNRKCHKALRQFPDR 210

QY 89 GPPALTHALLFCGCGEGPACARRROTFAFACAFSGPOLAPSCCLKPDRCSRRRCRPL 148
DB 211 VSESYTYRMLFSCGQOQACERRRQITLPSCTYEDKE--KPNCLDRSLCRTDHLCRSL 268

QY 149 FAFQASCAPAPGSRDCCPEEGGPRCLRAYAGLVGTVPNTYLDN--VSARVAPWCGCEAS 206
DB 269 ADFHANCRASTYRTITSCPADNYQACLSYAGMIGFDMTPNYVDSNPTGIIVSPWNCRCGS 328

QY 207 GNRRECEAFRLKFTFNPCLDGAIOAF 233
DB 329 GNMEECEKFLDFTENPCLRNAIOAF 355

RESULT 5
US-08-802-805D-6
Sequence 6, Application US/0802805D
Patent No. 6372453
GENERAL INFORMATION:
APPLICANT: Robert D. Klein
TITLE OF INVENTION: Neurturin Receptor
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/802,805D
FILING DATE: 18-Feb-1997
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, PhD., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P1086
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 464 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-802-805D-6

Query Match 33.2%; Score 469; DB 3; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASTEGNRCVEAAEACTADECCQQLRSEVVAOCLGAGRGSGSCVRSRCRRLRRFPAR 88
DB 153 AVSTSNHCLDAKACNLNDNCKLRSSYISICNREIS--PTERCNRKCHKALRQFPDR 210

QY 89 GPPALTHALLFCGCGEGPACARRROTFAFACAFSGPOLAPSCCLKPDRCSRRRCRPL 148
DB 211 VSESYTYRMLFSCGQOQACERRRQITLPSCTYEDKE--KPNCLDRSLCRTDHLCRSL 268

DB 211 VSESYTYRMLFSCGQOQACERRRQITLPSCTYEDKE--KPNCLDRSLCRTDHLCRSL 268

QY 149 FAFQASCAPAPGSRDCCPEEGGPRCLRAYAGLVGTVPNTYLDN--VSARVAPWCGCEAS 206
DB 269 ADFHANCRASTYRTITSCPADNYQACLSYAGMIGFDMTPNYVDSNPTGIIVSPWNCRCGS 328

QY 207 GNRRECEAFRLKFTFNPCLDGAIOAF 233
DB 329 GNMEECEKFLDFTENPCLRNAIOAF 355

RESULT 6
US-08-861-990-2
Sequence 2, Application US/0861990
Patent No. 6636259
GENERAL INFORMATION:
APPLICANT: Ibanez, Carlos F.
APPLICANT: Arumae, Urmas
APPLICANT: Sariola, Hannu
APPLICANT: Suanto, Petro
APPLICANT: Tuppi, Miles
APPLICANT: Saarna, Mart
TITLE OF INVENTION: Glial Cell Line-Derived Neurotrophic Factor Receptors
FILE REFERENCE: CEPH0418
CURRENT APPLICATION NUMBER: US/08/861,990
PRIOR FILING DATE: 1997-05-22
PRIOR APPLICATION NUMBER: 08/747,842
PRIOR FILING DATE: 1996-11-13
PRIOR APPLICATION NUMBER: 60/006,619
PRIOR FILING DATE: 1995-11-13
PRIOR APPLICATION NUMBER: 60/015,767
PRIOR FILING DATE: 1996-04-16
PRIOR APPLICATION NUMBER: 60/021,965
PRIOR FILING DATE: 1996-06-27
PRIOR APPLICATION NUMBER: 60/020,638
PRIOR FILING DATE: 1996-06-27
PRIOR APPLICATION NUMBER: 60/020,639
PRIOR FILING DATE: 1996-06-27
NUMBER OF SEQ ID NOS: 11
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 2
LENGTH: 464
TYPE: PRT
ORGANISM: Rattus sp.
US-08-861-990-2

Query Match 33.2%; Score 469; DB 4; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASTEGNRCVEAAEACTADECCQQLRSEVVAOCLGAGRGSGSCVRSRCRRLRRFPAR 88
DB 153 AVSTSNHCLDAKACNLNDNCKLRSSYISICNREIS--PTERCNRKCHKALRQFPDR 210

QY 89 GPPALTHALLFCGCGEGPACARRROTFAFACAFSGPOLAPSCCLKPDRCSRRRCRPL 148
DB 211 VSESYTYRMLFSCGQOQACERRRQITLPSCTYEDKE--KPNCLDRSLCRTDHLCRSL 268

QY 149 FAFQASCAPAPGSRDCCPEEGGPRCLRAYAGLVGTVPNTYLDN--VSARVAPWCGCEAS 206
DB 269 ADFHANCRASTYRTITSCPADNYQACLSYAGMIGFDMTPNYVDSNPTGIIVSPWNCRCGS 328

QY 207 GNRRECEAFRLKFTFNPCLDGAIOAF 233
DB 329 GNMEECEKFLDFTENPCLRNAIOAF 355

RESULT 7
US-09-388-316C-6
Sequence 6, Application US/09388316C
Patent No. 6777196
GENERAL INFORMATION:
APPLICANT: KLEIN, ROBERT D.


```

; LENGTH: 664 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 18
US-09-487-665-18

```

Query Match	33.2%;	Score 469;	DB 3;	Length 664;
Best Local Similarity	43.0%;	Pred. No. 2.8e-35;		
Matches	89;	Mismatches	33;	Indels 6;
				Gaps 3

OY 29 ASSTGNRCVTEAAEACTADECCQQLASVEVAOCLGRAGWRGFS CVTSRCPRLALRRFFPAR 88
 ||| : |::|| :::||:| ::| : |:|:|
D6 153 AVSTSNNHCDADAKACNLNDNCCKLASSYSISCNREIS--PTERCNRRKCHKALRQFEDR 210

```

0y      89  GPALTHALLFCGCEBPACARRRQTPAPAC.FSGPLAPSLKPLDRCESRRRCRRRL 148
          |  :::::|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
db      211 VPSEYTYRMFLFCSCDQACARRRQTLTPSCSYBDE--KPNCLDLASLCRTDHLCSRL 268

```

```

0y 149 FAFQASCAPAGSRDCEEGPRCLRAYAGLVGTVTPTNYLDN--VSARVAPWCGEAS 206
      |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 269 ADFHANCRAVRTITSCPADNYQACLGSYAGIGFDMTPNYVDSNPFGIIVSPWCNCRGS 328

```

```
QY      207  GNRRRECEAFRLFTRNPCLDGAIQAF 233
          ||| ||| : ||| ||| |||
Db      329  GNMEEECEKFLRDTENPCLRNAIQAF 355
```

RESULT 10
US-08-802-805D-18
; Sequence 18, Application US/08802805D
; Patent No. 6372453

```

;
; GENERAL INFORMATION:
;
; APPLICANT: Robert D. Klein
;
; TITLE OF INVENTION: Neurturin Receptor
;
; NUMBER OF SEQUENCES: 28
;
; CORRESPONDENCE ADDRESS:
;

```

```

1  COMPUTER READABLE FORM:
2  MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
3
4  COMPUTER: IBM PC compatible
5
6  OPERATING SYSTEM: PC-DOS/MS-DOS
7
8  SOFTWARE: Winpatin (Genentech)
9
10 CURRENT APPLICATION DATA:
11
12 APPLICATION NUMBER: US/08/802,805D
13
14 FILING DATE: 18-Feb-1997

```

Oy 29 ASSTGNCRCVEAEACTADECCQQLSELYVAQCIGRAGWRGSGCVNSRCREALRRFEAR 98
| | :
Db 153 AVSTGSNHCIDAAKACNLNDNCCKLASSYISTCNRETSPETERCNRKKCHALROFFDR 210

[illegible]

RESULT 11
US-09-388-316C-18
; Sequence 18, Application US/09388316C
; Patent No. 6777196
; GENERAL INFORMATION:

```

1  APPLICANT: KLEIN, ROBERT D.
2  APPLICANT: ROSENTHAL, ARRON
3  APPLICANT: HYNES, MARY A.
4  TITLE OF INVENTION: NEURITRIN RECEPTOR
5  FILE REFERENCE: GENEENT.45A2DV1
6  CURRENT APPLICATION NUMBER: US/09/388,316C
7  CURRENT FILING DATE: 1999-09-01
8  PRIOR APPLICATION NUMBER: 09/024,665
9  PRIOR FILING DATE: 1998-02-17
10 PRIOR APPLICATION NUMBER: 60/063,258
11 PRIOR FILING DATE: 1997-10-24
12 PRIOR APPLICATION NUMBER: 60/049,818
13 PRIOR FILING DATE: 1997-06-09
14 PRIOR APPLICATION NUMBER: 60/038,839
15 PRIOR FILING DATE: 1997-02-18
16 NUMBER OF SEQ ID NOS: 30
17 SOFTWARE: FastSeq for Windows Version 4.0
18 SEQ ID NO 18
19 LENGTH: 664
20 TYPE: PRT
21 ORGANISM: Artificial Sequence
22 FEATURE:
23 OTHER INFORMATION: This sequence is a fusion protein comprising rat
24 US-09-388-316C-18
25 OTHER INFORMATION: NTRalpha sequence and human Fc sequence.

```

Query Match	33.2%;	Score 469;	DB 4;	Length 664;
Best Local Similarity	43.0%;	Pred. No. 2.8e-35;		
Matches	89;	Conservative	33;	Mismatches 79;
			Indels	6;
			Gaps	3

Qy 29 ASSVEGNRCYEAARECTAAECCQQDQRSEVYAQCIGAGMGWPGSCYRSCRALRRFFAR 88
| | :
Db 153 AVSTKSNHCLDAAYACNLNDNCCKLRSSYSISICNRBIS--PTERCNRRKCHAKALRPFPDR 210

```

09  GPAPALHALLUFGCEGGACAEKRRKKIIFAPALAFSGPGLAPPSCLKLPADRCESBKKCKRKL 148
      | : : : : | : : : : | : : : : | : : : : |
211 VPSEVYTRNMLFCSCDDQACAEKRRKPTILPSCSYEDKE--KENCLDLRLSLCTIDHLGSRSL 268

```

Df

269 ADFFANCRASRYRTITSCPADNYQACLGSYAGMIGFDMTPPNVDSNPTGIWVSPMCNCRGSS 328

QY 207 GNREECEAFRKLFTRNPPCLDGAIQAF 233
||| : |||||
Db 329 GNMEECEKFLRDFTENPCLRNAIQAF 355

RESULT 12
US-09-187-906-9
; Sequence 9, Application US/09187906

GENERAL INFORMATION:
APPLICANT: BIOGEN INC.
TITLE OF INVENTION: Ret Ligand (RetL) for Stimulating Neuronal and Renal Growth
TITLE OF INVENTION: Ret Ligand (RetL) for Stimulating Neuronal and Renal Growth

```

NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSER: Biogen, Inc.
STREET: 14 Cambridge Center
CITY: Cambridge
STATE: MA
COUNTRY: USA
ZIP: 02142
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/187,906
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US97/07726
FILING DATE: 07-MAY-97
APPLICATION NUMBER: US 60/017,427
FILING DATE: 08-MAY-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/019,300
FILING DATE: 07-JUN-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/021,859
FILING DATE: 16-JUL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/043,533
FILING DATE: 10-APR-97
ATTORNEY/AGENT INFORMATION:
NAME: Kaplan, Warren A.
REGISTRATION NUMBER: 34,199
REFERENCE/DOCKET NUMBER: A008 PCT CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-679-2400
TELEX: 617-679-2838
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 346 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-187-906-9

Query Match      32.9%; Score 465; DB 4; Length 346;
Best Local Similarity 41.9%; Pred. No. 3,1e-35;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3

QY      33 EGNRCVEAEACTADECCQLAEEVVAOCLGAGNRGGSCYRSRCRRALREFARGPPA 92
       :|::||::||::||::||::||::||::||::||::||::||::||::||::||
DB      31 KGNKCLDAAKACNLDIDICKYSASVITTCITTSV--SNDVCRRRCRCHXALROFPDKVP 87
       :|::||::||::||::||::||::||::||::||::||::||::||::||

QY      93 LTHALLFGCGSGPACAERRRQTFEAFACAFSGPOLAPSPGLKPLDLCERSRRRPRLFA 152
       :|::||::||::||::||::||::||::||::||::||::||::||::||
DB      88 HSYGMLFSCSDIADICTERRROTIVVCYE--EREKNCLMIQDSCKTNYICRSLADF 145
       :|::||::||::||::||::||::||::||::||::||::||::||::||

QY      153 ASCAPAPSGRDCCPEEGPRCILRAYAGLVGTVTNTYIDLNV SARVAPMGCEASGNRREE 212
       :|::||::||::||::||::||::||::||::||::||::||::||::||
DB      146 TNCOPESRSVSCLKENYADCDLAYSGLIGVTMTNTYIDSSLSVAAPWDCGNSGNDLEE 205
       :|::||::||::||::||::||::||::||::||::||::||::||::||

QY      213 CEAFPKLPTRNPCLDGAIOAFDSSQPSVLQOQWNP 247
       :|::||::||::||::||::||::||::||::||::||::||::||::||
DB      206 CLKFLNPFKYNTCLKNALIAFGNGSDVTV---WQP 237
       :|::||::||::||::||::||::||::||::||::||::||::||::||

RESULT 13
US-08-802-805D-22
Sequence 22, Application US/08802805D
Patent No. 6372453
GENERAL INFORMATION:
APPLICANT: Robert D. Klein

```

1 TITLE OF INVENTION: Neurturin Receptor
2 NUMBER OF SEQUENCES: 28
3 CORRESPONDENCE ADDRESS:
4 ADDRESSEE: Genentech, Inc.
5 STREET: 1 DNA Way
6 CITY: South San Francisco
7 STATE: California
8 COUNTRY: USA
9 ZIP: 94080
10
11 COMPUTER READABLE FORM:
12 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
13 COMPUTER: IBM PC compatible
14 OPERATING SYSTEM: PC-DOS/MS-DOS
15 SOFTWARE: Winpatin (Genentech)
16 CURRENT APPLICATION DATA:
17 APPLICATION NUMBER: US/08/802,805D
18 FILING DATE: 18-Feb-1997
19
20 CLASSIFICATION: 536
21 ATTORNEY/AGENT INFORMATION:
22 NAME: Torchia, PhD., Timothy E.
23 REGISTRATION NUMBER: 36,700
24 REFERENCE/DOCKET NUMBER: P1086
25 TELECOMMUNICATION INFORMATION:
26 TELEPHONE: 650/225-8674
27 TELEFAX: 650/952-9881
28
29 INFORMATION FOR SEQ ID NO: 22:
30 SEQUENCE CHARACTERISTICS:
31 LENGTH: 460 amino acids
32 TYPE: Amino Acid
33 TOPOLOGY: Linear
34
35 JS-08-802-805D-22

```

Query Match      32.9% ; Score 465; DB 3; Length 460;
Best Local Similarity 41.9%; Pred. No. 4.3e-35;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY      33 EGNRCVBAABACTADECCOQLRSEYVAQCLGRAGMRPGSCVRSRCRRALRFPAFGPPA 92
       .:::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db      145 KANNCLDPAKACNDDICKKYSAYINPCITSV---SNDVCNRKRCKHAKLRQFDKVPK 201
       |:::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
QY      93 LTHALLFCGCEGPACARRRQTTPAPACAFSGPOLAPSPCLKPLDRCSRRCRPRLPAFQ 152
       ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db      202 HSYGMLEFCSRDIACTERRQITVPVCSYE--EREKENCINTLPDSCTNTNYCRGLADFF 259
       ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
QY      153 ASCAPAPGSRDGCPEEGPRCLRAYAGLNGVTYPNTLDNVSAVAWMCGEASGNREE 212
       .:::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db      260 TNCQPERSVSSCLKEKYADCLANLSLTIGTWIPNTIDSSLVASAPMCDCSNGNDLEE 319
       .:::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
QY      213 CEAFERKLFTNNPCLDGAIOAFDSQSPEVLDDOWNP 247
       .:::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db      320 CLKELNFKNQNTCLKNAIQAFGNSDVTV---WQP 351
       .:::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

RESULT 14
US-09-187-906-11
; Sequence 11, Application US/09187906
; Patent No. 6677135
; GENERAL INFORMATION:
; APPLICANT: BIOGEN, INC.
; TITLE OF INVENTION: Ret Ligand (RetL) for Stimulating Neural
; TITLE OP INVENTION: and Renal Growth
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Biogen, Inc.
; STREET: 14 Cambridge Center
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02142
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```


SQ Sequence 258 AA;

Query Match 100.0%; Score 1413; DB 4; Length 258;
 Best Local Similarity 100.0%; Pred. No. 2.1e-123;
 Matches 258; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLSGAYLRVLTNRPGQAVLMSIGCGSGASSTEGNRCVEAAEAACCTADECCQQLRSEYVAQ 60
 DB 1 MLSGAYLRVLTNRPGQAVLMSIGCGSGASSTEGNRCVEAAEAACCTADECCQQLRSEYVAQ 60
 QY 61 CLGRAGMRPGSGCVSRRCRRALRRFPARGPPALTHALLFCGCEGPACAEERRQTAPACA 120
 DB 61 CLGRAGMRPGSGCVSRRCRRALRRFPARGPPALTHALLFCGCEGPACAEERRQTAPACA 120
 QY 121 FSGPOLAPPSCLEPDRCSRRRCRPLFAFQASCAPAGSRDGCPEGGPRCLRAYAGL 180
 DB 121 FSGPOLAPPSCLEPDRCSRRRCRPLFAFQASCAPAGSRDGCPEGGPRCLRAYAGL 180
 QY 181 VGTVTVPNYLDNVSARVAPWCGCEASGNRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 DB 181 VGTVTVPNYLDNVSARVAPWCGCEASGNRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 QY 241 LODQNPYQNAQAAYEA 258
 DB 241 LODQNPYQNAQAAYEA 258

RESULT 2
 AAB61636
 ID AAB61636 standard; protein; 273 AA.
 AC AAB61636;
 DT 06-APR-2001 (first entry)
 DE Rat GFRA1pha-4 splice variant A.
 XX Rat; GFRA1pha-4; carcinoma; familial hirschsprung disease; pain;
 KW glial cell-line derived neurotrophic factor; neurodegenerative disease;
 KM GDNF family receptor alpha-4; Alzheimer's disease; Parkinson's disease;
 KW motor neuron disease; peripheral neuropathy; spinal cord injury;
 KM chromosome 3q35.
 OS Rattus rattus.
 XX WO200102557-A1.
 PN 11-JAN-2001.
 PD 26-MAY-2000; 2000WO-EP004918.
 PF 29-JUN-1999; 99GB-00015200.
 PR (JANC) JANSEN PHARM NV.
 PA Measure SLJ, Cik M, Hoefnagel EW;
 PI WPI; 2001-138137/14.
 DR N-PSDB; AAF31061, AAF31062.
 XX Glial cell-line derived neurotrophic factor family receptor alpha-4,
 PT useful for preparing medicaments for treating neurodegenerative diseases
 PT (e.g. Alzheimer's disease, Parkinson's disease) and carcinomas.
 PS Claim 14; Page 73-74; 82pp; English.
 XX The present sequence is rat Glial cell-line Derived Neurotrophic Factor
 CC (GDNF) family receptor alpha-4 (GFRA1pha-4) splice variant A. GFRA1pha-4
 CC is useful in the preparation of a medicament for the treatment of
 CC neurodegenerative diseases, Alzheimer's disease, Parkinson's disease,
 CC motor neuron disease, peripheral neuropathy, spinal cord injury, familial
 CC hirschsprung disease, carcinomas, and diseases associated with GFRA1pha-4
 CC receptor dysfunction and in alleviating pain. The rat-GFRA1pha-4 gene

CC (see AAF31061) is localised on chromosome 3q36

SQ Sequence 273 AA;

Query Match 98.1%; Score 1386; DB 4; Length 273;
 Best Local Similarity 100.0%; Pred. No. 7.5e-121;
 Matches 252; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLSGAYLRVLTNRPGQAVLMSIGCGSGASSTEGNRCVEAAEAACCTADECCQQLRSEYVAQ 60
 DB 1 MLSGAYLRVLTNRPGQAVLMSIGCGSGASSTEGNRCVEAAEAACCTADECCQQLRSEYVAQ 60
 QY 61 CLGRAGMRPGSGCVSRRCRRALRRFPARGPPALTHALLFCGCEGPACAEERRQTAPACA 120
 DB 61 CLGRAGMRPGSGCVSRRCRRALRRFPARGPPALTHALLFCGCEGPACAEERRQTAPACA 120
 QY 121 FSGPOLAPPSCLEPDRCSRRRCRPLFAFQASCAPAGSRDGCPEGGPRCLRAYAGL 180
 DB 121 FSGPOLAPPSCLEPDRCSRRRCRPLFAFQASCAPAGSRDGCPEGGPRCLRAYAGL 180
 QY 181 VGTVTVPNYLDNVSARVAPWCGCEASGNRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 DB 181 VGTVTVPNYLDNVSARVAPWCGCEASGNRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 QY 241 LODQNPYQNAQAAYEA 252
 DB 241 LODQNPYQNAQAAYEA 252

RESULT 3
 AAB62103
 ID AAB62103 standard; protein; 277 AA.
 AC AAB62103;
 DT 29-MAY-2001 (first entry)
 DE Mouse RetL5 polypeptide.
 XX RetL5 polypeptide.
 KW Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KW vulnerability; neurotropic; anti-HIV; neuroprotective; antibacterial;
 KW cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 OS Mus sp.
 XX WO200116169-A2.
 PN 08-MAR-2001.
 PD 01-SEP-2000; 2000WO-US024111.
 PE 01-SEP-1999; 99US-0152024P.
 PF (BIOJ) BIOGEN INC.
 PA ~~Wetley~~ D;
 PI WPI; 2001-235091/24.
 DR N-PSDB; AAF57270.
 XX Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 CC cell that expresses Ret and for modulating Ret signal transduction
 CC involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX Claim 13; Fig 3; 76pp; English.

CC The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimerization or autophosphorylation activator. The polypeptides and their
 CC antibodies are useful for stimulating growth of or limiting damage to,
 CC Ret expressing tissue in a subject, for suppressing growth of a tumour
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 CC a cell expressing the Ret polypeptide. The RetL5 transduction involving
 CC proteins containing RetL5 and antibodies are useful for stimulating renal
 CC tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic
 CC syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 CC such as neural degeneration where neural growth and regeneration are
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events
 CC such as hemorrhage or emboli, and neural disorders such as mental
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
 CC palsy. The present sequence represents the mouse RetL5 polypeptide
 CC predicted by visual inspection method
 CC
 XX Sequence 277 AA;

Query Match 76.3%; Score 1078; DB 4; Length 277;
 Best Local Similarity 87.4%; Pred. No. 4,1e-92;
 Matches 201; Conservative 7; Mismatches 14; Indels 8; Gaps 2;

QY 27 GSASSTEGRCVCEAEACTADBCOQLSEVYAOCIGRA---GMRPGSCVSRRCRRALR 83
 DB 16 GSASFTDGNRCVDAEACTADBCOQLSEVYARCLGRAPGRRPGGCVSRRCRRALR 75
 QY 84 RFFARGPALTYALLFCGCEGPAACERRRQTAPAPACAFSGPOLAPPSCLEPDRCSRR 143
 DB 76 RFFARGPALTYALLFCGCEGPAACERRRQTAPAPACAFSGPOLAPPSCLEPDRCSRR 135
 QY 144 CRPLFAFOASCAPAPGSRDGCPEEGGPRCLRAYAGLVGTVTTPNYLDNVARSAPVWC 203
 DB 136 CRPLFAFOASCAPAPGSRDGCPEEGGPRCLRAYAGLVGTVTTPNYLDNVARSAPVWC 195
 QY 204 EASGNRRECEAFRLFTNPNCLDGAIOAFDSGSPSVLQDQNNPYNQAO 253
 DB 196 AASGNRRECEAFRLFTNPNCLDGAIOAFDSGSPSVLQD-----QTAQO 240

RESULT 4

ID AAB62107 standard; protein; 476 AA.

XX AAB62107;

DT 29-MAY-2001 (first entry)

DE Murine RetL5/human IgG Fc fusion protein.

KM Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KM Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KM vulnerable; neurotropic; anti-HIV; neuroprotective; antibacterial;
 KM cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic;
 KM IgG; fusion protein; GDNF; neublastin; NEN.

OS Mus sp.

XX WO200116169-A2.

XX 08-MAR-2001.

PF 01-SEP-2000; 2000WO-US024111.

XX

PR 01-SEP-1999; 99US-0152024P.

XX (BIOI) BIOGEN INC.

XX Worley D;

DR WPI; 2001-235091/24.

PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.

PS Example 10; Page 39-40; 76pp; English.

CC The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimerization or autophosphorylation activator. The polypeptides and their
 CC antibodies are useful for stimulating growth of or limiting damage to,
 CC Ret expressing tissue in a subject, for suppressing growth of a tumour
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 CC a cell expressing the Ret polypeptide. The RetL5 transduction involving
 CC proteins containing RetL5 and antibodies are useful for stimulating renal
 CC tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic
 CC syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 CC such as neural degeneration where neural growth and regeneration are
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events
 CC such as hemorrhage or emboli, and neural disorders such as mental
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
 CC palsy. The present sequence represents a murine RetL5 and a human IgG Fc
 CC fusion protein. This fusion protein interacts with GDNF family member
 CC neublastin, NEN
 CC
 XX Sequence 476 AA;

Query Match 76.3%; Score 1078; DB 4; Length 476;
 Best Local Similarity 87.4%; Pred. No. 7,6e-92;
 Matches 201; Conservative 7; Mismatches 14; Indels 8; Gaps 2;

QY 27 GSASSTEGRCVCEAEACTADBCOQLSEVYAOCIGRA---GMRPGSCVSRRCRRALR 83
 DB 16 GSASFTDGNRCVDAEACTADBCOQLSEVYARCLGRAPGRRPGGCVSRRCRRALR 75
 QY 84 RFFARGPALTYALLFCGCEGPAACERRRQTAPAPACAFSGPOLAPPSCLEPDRCSRR 143
 DB 76 RFFARGPALTYALLFCGCEGPAACERRRQTAPAPACAFSGPOLAPPSCLEPDRCSRR 135
 QY 144 CRPLFAFOASCAPAPGSRDGCPEEGGPRCLRAYAGLVGTVTTPNYLDNVARSAPVWC 203
 DB 136 CRPLFAFOASCAPAPGSRDGCPEEGGPRCLRAYAGLVGTVTTPNYLDNVARSAPVWC 195
 QY 204 EASGNRRECEAFRLFTNPNCLDGAIOAFDSGSPSVLQDQNNPYNQAO 253
 DB 196 AASGNRRECEAFRLFTNPNCLDGAIOAFDSGSPSVLQD-----QTAQO 240

RESULT 5

ID AAB62106 standard; protein; 260 AA.

XX AAB62106;

DT 29-MAY-2001 (first entry)

DE Mouse RetL5 alternatively spliced polypeptide.

XX Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KW vulnerability; neurotropic; anti-HIV; neuroprotective; antibacterial;
 KW cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 OS Mus sp.
 XX
 XX MO200116169-A2.
 XX
 XX 08-MAR-2001.
 XX
 XX 01-SEP-2000; 2000WO-US024111.
 XX
 XX 01-SEP-1999; 99US-0152024P.
 XX
 XX (BIO) BIOGEN INC.
 XX
 XX Worley D;
 XX
 XX WPI; 2001-235091/24.
 XX N-PSDB; AAF57273.
 DR
 XX Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX
 PS Disclosure; Fig 8; 76pp; English.
 XX
 XX The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimerization or autophosphorylation activator. The polypeptides and their
 CC antibodies are useful for stimulating growth of or limiting damage to,
 CC Ret expressing tissue in a subject, for suppressing growth of a tumor
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 CC a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion
 CC proteins containing RetL5 and antibodies are useful for stimulating renal
 CC tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic
 CC syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 CC such as neural degeneration where neural growth and regeneration are
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events
 CC such as hemorrhage or emboli, and neural disorders such as mental
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
 CC palsy. The present sequence represents an alternatively spliced mouse
 CC RetL5 polypeptide
 CC
 XX
 XX Sequence 260 AA;
 SQ
 Query Match 76.1%; Score 1075.5; DB 4; Length 260;
 Best Local Similarity 89.6%; Pred. No. 6.5e-92;
 Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;

QY 27 GSASSTEGNRCVEAAEACTADQCQOLRSEYVAQCIGRA---GMRGPGSCVSRRCRRALR 83
 DB 16 GSASFTDNRNCVDAAEAECTADRCQQLRSEYVARCIGLAAGRGPRGCGCRSRARR 75
 QY 84 RFPARGPALTHALLFCGCEGPACAEERRRQTFAPACAFSGQLAPPSCLEPLDRCESRR 143
 DB 76 RFPARGPALTHALLFCGCEGSACAERRRQTFAPACAFSGGLVPPSCLEPLERCESRR 135
 QY 144 CRPLFAFOASCAPAPSGSDGCPBEGGPRCLRAVAGLVGTVPNTNYLDNVSARVAPWCGC 203
 DB 136 CRPLFAFOASCAPAPSGSDGCPBEGGPRCLRAVAGLVGTVPNTNYLDNVSARVAPWCGC 195

QY 204 EASGNRECEAFRLFTRNPCLDGAIQAFDSQPSVLODQ 244
 DB 196 AASGNRRECEAFRLFTRNPCLDGAIQAFDSQPSVLODQ 236

RESULT 6
 ABB09214
 ID ABB09214 standard; protein, 260 AA.
 XX
 XX ABB09214;
 AC
 AC 08-JUL-2002 (first entry)
 DT
 XX
 DE Mouse GPI-anchored isoform a1 protein SEQ ID NO:1.
 KW GFRA1pha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosolic;
 KW glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KW glial cell line derived neurotrophic factor; osteopathic; tumour;
 KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KW neuronal disorder; aberrant axonal sprouting.
 XX
 OS Mus musculus.
 XX
 XX WO200162795-A1.
 XX
 XX 30-AUG-2001.
 XX
 XX 14-NOV-2000; 2000WO-FI000994.
 XX
 XX 21-FEB-2000; 2000FI-00000394.
 XX
 XX (LICE-) LICENTIA LTD.
 XX
 XX Atrakainen M, Saarna M, Poterlaev D, Lindahl M, Timmusk T;
 PI Rossi U;
 XX
 DR WPI; 2001-596722/67.
 XX N-PSDB; ABL51669.
 XX
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT nervous cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR) alpha4.
 XX
 PS Claim 9; Fig 1B5; 143pp; English.
 XX
 XX The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR) alpha4, or its fragments. GFRA1pha4 sequences have cytosolic,
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRA1pha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRA1pha4
 CC polynucleotide sequence can be used for recording GFRA1pha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRA1pha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC neoplasia, endocrine tumours, medullary thyroid carcinoma and
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the mouse GFRA1pha4 protein, designated GPI-anchored
 CC isoform a1, from the present invention
 CC
 XX
 XX Sequence 260 AA;
 SQ
 Query Match 76.1%; Score 1075.5; DB 4; Length 260;
 Best Local Similarity 89.6%; Pred. No. 6.5e-92;
 Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;

QY 27 GSASSTEGNRCVEAAEACTADQCQOLRSEYVAQCIGRA---GMRGPGSCVSRRCRRALR 83

Db 16 GSASFTDGNRCVDAABACTADDERCOQLRSEYVARCLGRAAPGRRPGGCVSRRCRRALR 75
 Qy 84 RFPARGPPALTYHALFFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCCLKPLDRCRSRR 143
 Db 76 RFPARGPPALTYHALFFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCCLKPLDRCRSRR 135
 Qy 144 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVTTPNYLDNVASRVAPWCGC 203
 Db 136 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVTTPNYLDNVASRVAPWCGC 195
 Qy 204 EASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 244
 Db 196 AASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 236
 RESULT 7
 ABB09215
 ID ABB09215 standard; protein; 293 AA.
 AC ABB09215;
 XX
 DT 08-JUL-2002 (first entry)
 XX
 DE Mouse putative transmembrane isoform a2 protein SEQ ID NO:2.
 XX
 KM GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
 KM glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KM gli1 cell line derived neurotrophic factor; osteopathic; tumour;
 KM neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KM medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KM neuronal disorder; aberrant axonal sprouting.
 XX
 OS Mus musculus.
 XX
 PN WO200162795-A1.
 XX
 PD 30-AUG-2001.
 XX
 PF 14-NOV-2000; 2000WO-FI000994.
 XX
 PR 21-FEB-2000; 2000FI-0000394.
 XX
 PA (LICE-) LICENTIA LTD.
 XX
 PI Aikarsinen M, Saarma M, Poterbaev D, Lindahl M, Timmusk T;
 PI Rossi J;
 DR MPI: 2001-596722/67.
 DR N-PSDB; ABL51670.
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR)alpha4.
 PS Claim 9; Fig 19B; 143pp; English.
 XX
 CC The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recoding GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be are used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC neoplasia, endocrine tumours, medullary thyroid carcinoma and
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the mouse GFRalpha 4 protein, designated putative

CC transmembrane isoform a2, from the present invention
 XX
 SQ Sequence 293 AA;
 Query Match 76.1%; Score 1075.5; DB 4; Length 293;
 Best Local Similarity 89.6%; Pred. No. 7.4e-92;
 Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;
 Qy 27 GSASFTDGNRCVDAABACTADDERCOQLRSEYVARCLGRAAPGRRPGGCVSRRCRRALR 83
 Db 16 GSASFTDGNRCVDAABACTADDERCOQLRSEYVARCLGRAAPGRRPGGCVSRRCRRALR 75
 Qy 84 RFPARGPPALTYHALFFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCCLKPLDRCRSRR 143
 Db 76 RFPARGPPALTYHALFFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCCLKPLDRCRSRR 135
 Qy 144 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVTTPNYLDNVASRVAPWCGC 203
 Db 136 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVTTPNYLDNVASRVAPWCGC 195
 Qy 204 EASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 244
 Db 196 AASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 236
 RESULT 8
 AAB62104
 ID AAB62104 standard; protein; 264 AA.
 AC AAB62104;
 XX
 DT 29-MAY-2001 (first entry)
 XX
 DE Mouse RetL5 polypeptide.
 XX
 KM Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KM Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KM vulnerable; neurotropic; anti-HIV; neuroprotective; antibacterial;
 KM cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 XX
 OS Mus sp.
 XX
 FH Key location/Qualifiers
 FT Peptide 1..21
 FT /note= "signal peptide"
 FT Protein 22..264
 FT /note= "mature protein"
 PN WO200116163-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 01-SEP-2000; 2000WO-US024111.
 XX
 PR 01-SEP-1999; 99US-0152024P.
 XX
 PA (BIOJ) BIOGEN INC.
 XX
 PI Worley D;
 DR MPI: 2001-235091/24.
 DR N-PSDB; AAF57271.
 PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX
 PS Claim 13; Fig 4; 76pp; English.
 XX
 CC The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimerization or autophosphorylation activator. The polypeptides and their

antibodies are useful for stimulating growth of or limiting damage to, Ret expressing tissue in a subject, for suppressing growth of a tumour cell that expresses Ret, for modulating Ret signal transduction involving a cell expressing the Ret polypeptide. The Ret's polypeptides, fusion proteins containing Ret's and antibodies are useful for stimulating renal tissue growth and/or survival, supporting renal function and minimizing damage to renal tissue after various insults, particularly for treating acute renal failure, acute nephritis, chronic renal failure, nephrotic syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic injury and trauma. The compounds are also useful for treating conditions such as neural degeneration where neural growth and regeneration are desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as motor neuron disease, demyelinating disease, bacterial diseases, viral diseases, and prion diseases including Creutzfeldt-Jakob disease. The compounds are also useful for treating disorders due to damage to neural tissue caused by neoplastic impingement, trauma or cerebrovascular events such as hemorrhage or emboli, and neural disorders such as mental retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral palsy. The present sequence represents the mouse Ret's polypeptide predicted from DSW300 sequence by GENSCAN/GENE ALEX

Sequence 264 AA;

Query Match 72.8%; Score 1028.5; DB 4; Length 264;
Best Local Similarity 86.9%; Pred. No. 1.6e-87;
Matches 192; Conservative 7; Mismatches 13; Indels 9; Gaps 2;

QY 27 GSASTEGNRCVEAEACTADBOCQULRSYVAOCLGRA---GMRFGSCVRSRCRALR 83
DB 16 GSASTEGNRCVEAEACTADBOCQULRSYVAOCLGRA---GMRFGSCVRSRCRALR 75
QY 84 RFFARGPALTHALLFCGCGGACABRRROTAPACAFSGPQLAPPSCLEPLDERCERSR 143
DB 76 RFFARGPALTHALLFCGCGGACABRRROTAPACAFSGPQLAPPSCLEPLDERCERSR 135
QY 144 CRPLFAFOASCAPAPSGRDGCEBEGPRCLRAVAGLVTVVTPNYLDNVSARVAPWCGC 203
DB 136 CR-----CASCAPAPSGRDGCEBEGPRCLRAVAGLVTVVTPNYLDNVSARVAPWCGC 189
QY 204 EASGNRRECEAFRLFTFRNPCLDGAIOAFDSOSPVLQDO 244
DB 190 AASGNRRECEAFRLFTFRNPCLDGAIOAFDSOSPVLQDO 230

RESULT 9
AAV42771
ID AAV42771 standard; protein; 340 AA.
XX
XX AAV42771;
AC
XX
XX
DT 05-JAN-2000 (first entry)
XX
XX
DE Murine glial derived neurotrophic factor receptor-alpha-X protein.
XX
XX Glial derived neurotrophic factor-alpha-X; GFR-alpha-X; neural cell;
XX survival; function; nervous system; signalling; diagnosis; treatment;
XX neurological disorder; sensory disorder; Djerjine-Roussey syndrome;
XX contralateral anaesthesia; eating disorder; obesity; motor disorder;
XX Parkinson's disease; amyotrophic lateral sclerosis; ALS;
XX cognitive disorder; Alzheimer's disease.
XX
XX
OS Mus sp.
XX
XX
FH Key Location/Qualifiers
FT Misc-difference 201
FT Misc-difference 217 /note= "Encoded by ANG"
FT Misc-difference 244 /note= "Encoded by AAN"
FT Misc-difference 340 /note= "Encoded by TG"
XX
XX
XX W0950298-A1.

XX
PD 07-OCT-1999
XX
XX
PF 25-MAR-1999; 99WO-US006631.
XX
XX
PR 31-MAR-1998; 98US-008070P.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX
PI Moore KJ;
XX
XX WPI: 1999-591276/50.
DR N-PEDB; AA228259.
XX
XX
PT A nucleic acid molecule that encodes GDNF Family Receptor alpha-X
PT protein, methods of isolation and antibodies - useful for the detection
PT of homologues and identification of binding compounds.
XX
XX
PS Claim 1; Fig 1; 100pp; English.

This sequence represents murine glial derived neurotrophic factor receptor-alpha-X (GFR-alpha-X) protein. GFR-alpha-X is a fourth member of the glial derived neurotrophic (GFR-alpha) family of receptors. The cDNA was identified in a positional cloning process in which the mouse mahogany locus was being sequenced to identify genes involved in obesity. The GFR-alpha-X protein binds to neurotrophic factors such as GDNF (glial cell line-derived neurotrophic factor) and/or NTN (neurturin), and mediates signalling within cells expressing the GFR-alpha-X protein. GFR-alpha-X, like the other three members of the GFR-alpha family (GFR-alpha-1, -2, and -3), transmits a signal to the interior of a cell by activation of the RRT protein tyrosine kinase signalling pathway. Neurotrophic factors promote survival and function of neural cells of both the central and peripheral nervous systems. Modulation of GFR-alpha-X activity can result in modulation of the neurotrophic factor-initiated cell function. Probes and/or primers derived from GFR-alpha-X cDNA, and antibodies against the protein are used to detect the presence of GFR-alpha-X nucleic acids or protein and can be used in the diagnosis and treatment of a variety of neurological disorders, including sensory disorders (e.g., Djerjine-Roussey syndrome, contralateral anaesthesia, and certain eating disorders), motor disorders (e.g., Parkinson's disease, amyotrophic lateral sclerosis), and cognitive disorders (e.g., Alzheimer's disease). In addition, compounds which bind to GFR-alpha-X may be used to modulate the activity of the protein

Sequence 340 AA;

Query Match 65.6%; Score 927; DB 2; Length 340;
Best Local Similarity 68.2%; Pred. No. 6.3e-78;
Matches 180; Conservative 10; Mismatches 28; Indels 46; Gaps 3;

QY 27 GSASTEGNRCVEAEACTADBOCQULRSYVAOCLGRA---GMRFGSCVRSRCRALR 83
DB 19 GSASTEGNRCVEAEACTADBOCQULRSYVAOCLGRA---GMRFGSCVRSRCRALR 78
QY 84 RFFARGPALTHALLFCGCGGACABRRROTAPACAFSGPQLAPPSCLEPLDERCERSR 143
DB 79 RFFARGPALTHALLFCGCGGACABRRROTAPACAFSGPQLAPPSCLEPLDERCERSR 138
QY 144 CRPLFAFOASCAPAPSGRDGCEBEGPRCLRAVAGLVTVVTPNYLDNVSARVAPWCGC 203
DB 139 CRPLFAFOASCAPAPSGRDGCEBEGPRCLRAVAGLVTVVTPNYLDNVSARVAPWCGC 198
QY 204 EASGNRRECEAFRLFTFRNPCLDGAIOAFDSOSPVLQDO 244
DB 199 AAKWKPARRMRSLEQALYXGTPAWVRGPGGEBRMSVAOSKLPGLVPTSHHWGGRW 258
QY 224 ---PCLDGAIOAFDSOSPVLQDO 244
DB 259 TVTCTHGDGAIOAFDSOSPVLQDO 282

RESULT 10
ABB09217

ID ABB09217 standard; protein; 269 AA.
 XX ABB09217;
 AC
 XX
 DT 08-JUL-2002 (first entry)
 XX
 DE Human GPI-anchored isoform a protein SEQ ID NO:4.
 XX
 KM GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
 KM glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KM glial cell line derived neurotrophic factor; osteopontin; tumour;
 KM neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KM medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KM neuronal disorder; aberrant axonal sprouting.
 XX
 OS Homo sapiens.
 XX
 PN WO200162795-A1.
 XX
 PD 30-AUG-2001.
 XX
 PF 14-NOV-2000; 2000WO-FI000994.
 XX
 PR 21-FEB-2000; 2000FI-00000394.
 XX
 PA (LICE-) LICENTIA LTD.
 XX
 PI Airaksinen M, Saarma M, Poterbaev D, Lindahl M, Timmusk T;
 PI Rosal J;
 XX
 DR WPI: 2001-596722/67.
 DR N-PSDB; ABL51672.
 XX
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR) alpha4.
 XX
 PS Claim 9; Fig 21B; 143pp; English.
 XX
 CC The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR) alpha4, or its fragments. GFRalpha4 sequences have cytoprotective,
 CC osteopontin, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recording GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the human GFRalpha 4 protein, designated GPI-anchored
 CC isoform a, from the present invention
 XX
 SQ Sequence 269 AA;
 Query Match 65.1%; Score 920.5; DB 4; Length 269;
 Best Local Similarity 78.3%; Pred. No. 1.9e-77;
 Matches 173; Conservative 11; Mismatches 34; Indels 3; Gaps 1;
 QY 27 GSASSTEGNRCEVEAEACTADECCOQLRSEYVAQCILGRAGMGPGSCVSRRCERALRRPF 86
 DB 16 GSASSTEGNRCEVEAEACTADECCOQLRSEYVAQCILGRAGMGPGSCVSRRCERALRRPF 72
 QY 87 AGGPAATLTHALLFCGCGEPACACERRRQTAPACAFSGPOLAPPSCILPDRCSRRCRP 146
 DB 73 AGGPAATLTHALLFCGCGEPACACERRRQTAPACAFSGPOLAPPSCILPDRCSRRCRP 132
 QY 147 RLPAPGASCAPAPGSHDGPBEGPRCLAYAGLVGTVTTPYLDVNSARVAPMCCGAS 206

DB 133 RLAFQVSTCPAPSPADGCLDQGARCLRAYAGLVGTATTPYVDVNSARVAPMCCGAS 192
 QY 207 GNRRECEAFRKLFTRNPCLDGAIQAFDSSQPSVLODQNP 247
 DB 193 GNRRECEAFRGLFTRNRCCLDGAIQAFASGWPVLLDQNP 233
 RESULT 11
 ID AAB62105 standard; protein; 282 AA.
 AC AAB62105;
 XX
 DT 29-MAY-2001 (first entry)
 XX
 DE Human RetL5 polypeptide.
 XX
 KM Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KM Alzheimer's disease; Parkinson's disease; Huntington's disease; human;
 KM vulnerrary; nootropic; anti-HIV; neuroprotective; antibacterial;
 KM cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..20
 FT Protein /note="signal peptide"
 FT Protein 21..282
 FT Protein /note="mature protein"
 XX
 PN WO200116169-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 01-SEP-2000; 2000WO-US024111.
 XX
 PR 01-SEP-1999; 99US-0152024P.
 XX
 PA (BIOV) BIOGEN INC.
 XX
 PI Worley D;
 PI WPI: 2001-235091/24.
 DR N-PSDB; AAF57272.
 XX
 PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX
 PS Claim 13; Fig 6; 76pp; English.
 XX
 CC The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimethylization or autophosphorylation activator. The polypeptides and their
 CC antibodies are useful for stimulating growth of or limiting damage to,
 CC Ret expressing tissue in a subject, for suppressing growth of a tumour
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 CC a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion
 CC proteins containing RetL5 and antibodies are useful for stimulating renal
 CC tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic
 CC syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 CC such as neural degeneration where neural growth and regeneration are
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events

CC such as hemorrhage or emboli, and neural disorders such as mental
CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
CC palsy. The present sequence represents the human Ret's polypeptide
XX

Sequence 282 AA;

Query Match 64.7%; Score 914.5; DB 4; Length 282;
Best Local Similarity 74.6%; Pred. No. 7.4e-77;
Matches 173; Conservative 15; Mismatches 41; Indels 3; Gaps 1;

27 GSASTEGNRCVEAEACTADECCQLRSEVVAQCIGRAGMGPSCVRSRCRALRRFF 86
16 GSASSVGNRCVDAEAECTADARCCRLRSEVVAQCIGRA--AAGGCRARCRALRRFF 72

87 ARGPPALTHALIFCGCEGPACAEERRRQTFAPACAFSGQLAPPSCLKPLDRCSRRCRP 146

73 ARGPPALTHALIFCGCAGPACAEERRRQTFVPSCAFSGGPAPPSCLEPLNFCERSRVCRP 132

147 RLFAFQASCAPAGSRDQCEGPRCLRAYAGLVGTVPYVLNNVSARVAPMCGCEAS 206

133 RLFAFQASCTPAPSAAPDGLDQGARCLRAYAGLVGTAVTPYVDNVSARVAPMCDGAS 192

207 GNRRECEAFRLFTRNPCLDGAIQAFDSQPSVLDQWNPYQNAQAKVEA 258

193 GNRREDCEAFRLFTRNPCLDGAIQAFASGWPVLLDQINPGDDEHSILQ 244

RESULT 12

ABB09218 standard; protein, 299 AA.

ABB09218;

08-JUL-2002 (first entry)

Human putative GPI-anchored isoform b protein SEQ ID NO:5.

GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytotactic;
glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
glial cell line derived neurotrophic factor; osteopathic; tumour;
neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
neural disorder; aberrant axonal sprouting.

Homo sapiens.

WO200162795-A1.

30-AUG-2001.

14-NOV-2000; 2000WO-FI000994.

21-FEB-2000; 2000FI-00000394.

(LICE-) LICENTIA LTD.

Airaksinen M, Saarna M, Poterlaev D, Lindahl M, Timmusk T;
Rossi J;

WPI; 2001-596722/67.

N-PSDB; ABL51673.

New nucleic acid sequence for manufacturing polypeptides for treating
PT endocrine cancers comprises a cDNA encoding a splicing isoform of
PT mammalian growth factor receptor (GFR)alpha4.

Claim 9; Fig 22B; 143pp; English.

The present invention describes an isolated and purified cDNA sequence
CC encoding a splicing isoform of a mammalian growth factor receptor
CC (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytotactic,
CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived

CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
CC polynucleotide sequence can be used for recoding GFRalpha4 mediated
CC signalling in neurons or endocrine cells such as thyroid calcitonin-
CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
CC polynucleotide sequences can be used for manufacturing polypeptides
CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
CC neoplasia, endocrine tumours, medullary thyroid carcinoma and
CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
CC preventing neuronal death or aberrant axonal sprouting. The present
CC sequence represents the human GFRalpha 4 protein, designated putative GPI
CC -anchored isoform b, from the present invention

Sequence 299 AA;

Query Match 54.3%; Score 767.5; DB 4; Length 299;
Best Local Similarity 62.5%; Pred. No. 4.1e-63;
Matches 157; Conservative 10; Mismatches 51; Indels 33; Gaps 3;

27 GSASTEGNRCVEAEACTADECCQLRSEVVAQCIGRAGMGPSCVRSRCRALRRFF 86

16 GSASSVGNRCVDAEAECTADARCCRLRSEVVAQCIGRA--AAGGCRARCRALRRFF 72

87 ARGPPALTHALIFCGCEGPACAEERRRQTFAPACAFSGQLAPPSCLKPLDRCSRRCRP 145

73 ARGPPALTHALIFCGCAGPACAEERRRQTFVPSCAFSGGPAPPSCLEPLNFCERSRVCRP 132

146 -----PRLFAFQASCAPAGSRDQCEGPRCLRAY 177

133 ARAAAGPWRGWRGLSPAHREPPAAQASPPGLSGLVHPSAQPRRLPAGPRPLPARLGP 192

178 AGL-VGTVPYTPYVDNVSARVAPMCGCEASGNRRECEAFRLFTRNPCLDGAIQAFASG 236

193 RGVPAAGTAVTPYVDNVSARVAPMCDGASGNRRECEAFRLFTRNPCLDGAIQAFASG 252

237 QPSVLDQWNP 247

253 WPVLLDQINP 263

RESULT 13

ABB09219 standard; protein, 182 AA.

ABB09219;

08-JUL-2002 (first entry)

Human putative soluble isoform c protein SEQ ID NO:6.

GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytotactic;
glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
glial cell line derived neurotrophic factor; osteopathic; tumour;
neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
neural disorder; aberrant axonal sprouting.

Homo sapiens.

WO200162795-A1.

30-AUG-2001.

14-NOV-2000; 2000WO-FI000994.

21-FEB-2000; 2000FI-00000394.

(LICE-) LICENTIA LTD.

Airaksinen M, Saarna M, Poterlaev D, Lindahl M, Timmusk T;
Rossi J;

DR WPI; 2001-596722/67.
 DR N-PSDB; ABL51674.
 XX
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR) alpha4.
 XX
 PS Claim 9; Fig 23B; 143bp; English.
 XX
 CC The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR) alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recording GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the human GFRalpha 4 protein, designated putative
 CC soluble isoform c, from the present invention
 CC
 SQ Sequence 182 AA;
 XX
 XX
 Query Match 46.0%; Score 649.5; DB 4; Length 182;
 Best Local Similarity 75.8%; Pred. No. 2,3e-52;
 Matches 122; Conservative 10; Mismatches 26; Indels 3; Gaps 1;
 QY 27 GSASSTEGRCYEAAEACTADCCOOLNSEYVAOCLGRAGMGPGSCVNSRCRRALRRP 86
 DB 16 GSASSVGNRCVDAAEACTADARCOQLNSEYVAOCLGRA--AQGCGPRARCRALRRP 72
 QY 87 AGFPALTALLFCGCEGPAACARRRQTAPACAFSGPOLAPPSCLKPLDRCSRRCP 146
 DB 73 AGFPALTALLFCGCEGPAACARRRQTAPACAFSGPOLAPPSCLKPLDRCSRRCP 132
 QY 147 RFAFQASCAPAGSRDGCPEEGPRCLRAYAGLVTVTP 187
 DB 133 RLAFOVSCTPAPSAADGCLDQAGARCLRAYAGLVGSPAP 173
 RESULT 14
 ABB09216
 ID ABB09216 standard; protein; 190 AA.
 XX
 AC ABB09216;
 XX
 DT 08-JUL-2002 (first entry)
 XX
 DE Mouse secreted isoform a3/4 protein SEQ ID NO:3.
 XX
 KW GFRalpha4, glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
 KW glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KW glial cell line derived neurotrophic factor; osteopathic; tumour;
 KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KW neuronal disorder; aberrant axonal sprouting.
 XX
 OS Mus musculus.
 XX
 FH Key Location/Qualifiers
 FT MISC-difference 85 /note= "encoded by CGC"
 FT MISC-difference 138 /note= "encoded by TGC"
 FT MISC-difference 139 /note= "encoded by GTC"
 FT

XX
 PN MO200162795-A1.
 XX
 PD 30-AUG-2001.
 XX
 PF 14-NOV-2000; 2000WO-FI000994.
 XX
 PR 21-FEB-2000; 2000FI-00000394.
 XX
 PA (LICE-) LICENTIA LTD.
 XX
 PI Alakselinen M, Saarna M, Poterlaev D, Lindahl M, Timmusk T;
 PI Roset J;
 XX
 DR WPI; 2001-596722/67.
 DR N-PSDB; ABL51671.
 XX
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR) alpha4.
 XX
 PS Claim 9; Fig 20B; 143bp; English.
 XX
 CC The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR) alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recording GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the mouse GFRalpha 4 protein, designated secreted
 CC isoform a3/4, from the present invention
 CC
 SQ Sequence 190 AA;
 XX
 XX
 Query Match 40.3%; Score 569.5; DB 4; Length 190;
 Best Local Similarity 64.7%; Pred. No. 7,1e-45;
 Matches 121; Conservative 8; Mismatches 33; Indels 25; Gaps 5;
 QY 27 GSASSTEGRCYEAAEACTADCCOOLNSEYVAOCLGRA--GMGPGSCVNSRCRRALR 83
 DB 16 GSASFTDGNRCVDAAEACTADRCOOLNSEYVACIGRAAPGPGGCGVNSRCRRALR 75
 QY 84 RFPARGPALTHALLFCGCEGPAACARRRQTAPACAFSGPOLAPPSCLKPLDRCSRR 143
 DB 76 RFPARGPALTHALLFCGCEGPAACARRRQTAPACAFSGPOLAPPSCLKPLDRCSRR 135
 QY 144 CRPLRFQASCAPAGSRDGCPEEGPRC-LRAYAGLVTVTPYLDNVSARVAPMG 202
 DB 136 CRV-----CRAG---RAGPLTRVARAGPVSLPSRPHAL-----PRAPATA 174
 QY 203 CEASGMR 209
 DB 175 ARRRGAR 181
 RESULT 15
 AAE05369
 ID AAE05369 standard; protein; 132 AA.
 XX
 AC AAE05369;
 XX
 DT 12-SEP-2001 (first entry)
 XX

Search completed: January 26, 2005, 13:12:23
Job time : 160 secs

```

DE Mouse Gdnf family receptor alpha 4 transmembrane isoform protein.
XX
XX Mouse; cytosolic; antiinflammatory; immunoregulatory; tissue integrity;
XX wound healing; immune response; vaccine; cancer; asthma; allergy;
XX Gdnf family receptor alpha 4 transmembrane isoform; cell trafficking;
XX therapy; Gfra4; secreted protein.
XX
OS Mus sp.
XX
XX MO200148192-A1.
XX
XX 05-JUL-2001.
XX
XX 21-DEC-2000; 2000WO-NZ000256.
XX
XX 23-DEC-1999; 99US-017678P.
XX
XX 28-NOV-2000; 2000US-00724864.
XX
XX (GENE-) GENESIS RES & DEV CORP LTD.
XX
XX Watson JD, Marison JG;
XX
XX WPI; 2001-425665/45.
XX
XX N-PSDB; AAD10139.
XX
XX Novel isolated polypeptide useful to isolate corresponding interacting
XX proteins or other compounds, to quantitatively determine levels of
XX interacting proteins or other compounds, and as therapeutic target.
XX
XX Claim 6; Page 93; 101pp; English.
XX
XX The patent discloses novel polynucleotides and their corresponding
XX proteins which play a major role in induction of growth, cell migration
XX and proliferation, cell-cell interaction and the differentiation of
XX tissue-specific cells. These proteins are important in the maintenance of
XX tissue integrity and thus are important in wound healing. They are useful
XX in various assays to determine the biological activity, to raise
XX antibodies, to isolate corresponding interacting proteins or other
XX compounds, to quantitatively determine levels of interacting proteins or
XX other compounds, and as therapeutic target in a whole range of disease
XX states. Compositions comprising the novel proteins of the invention are
XX useful for treating mammalian disorders. Polynucleotides of the invention
XX are useful in genome and physical mapping, in positional cloning of
XX genes, to tag or identify an organism or its reproductive material (as
XX non-disruptive tags for marking organisms), and for the diagnosis and
XX treatment of mammalian diseases which is the consequence of inappropriate
XX expression of kinase genes. They are useful for promoting immune response
XX as part of a vaccine or anti-cancer treatment, as target for cancer
XX treatment, as immunoregulatory and anti-inflammatory molecule, as
XX diagnostic for specific types of cancer and for development of an anti-
XX cancer treatment, and as a target for antagonists in the treatment of
XX diseases such as asthma and allergy. They are also useful to inhibit or
XX enhance the activity of the soluble molecule that binds proteins of the
XX invention, for tissue and neural regeneration, to promote or block cell
XX trafficking, and as anti-inflammatory and/or vaccine adjuvant. The
XX present sequence is mouse Gdnf family receptor alpha 4 (Gfra4)
XX transmembrane isoform
XX
XX Sequence 132 AA;
XX
XX Query Match 36.4%; Score 515; DB 4; Length 132;
XX Best Local Similarity 94.0%; Pred. No. 5,6e-40;
XX Matches 94; Conservative 1; Mismatches 5; Indels 0; Gaps 0;
XX
XX 145 RPRLAFQASCAPAGSRDGCPEGGRCLRAYAGTGTVTPTNTLDNVSARVAPWCGCE 204
XX |||||
XX 9 RPRLAFQASCAPAGSRDGCPEGGRCLRAYAGTGTVTPTNTLDNVSARVAPWCGCA 68
XX
XX 205 ASGNRRECEAFRLFTNPCLDGA1QAFDSSQSPVLQDO 244
XX |||||
XX 69 ASGNRRECEAFRLFTNPCLDGA1QAFDSSQSPVLQDO 108

```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 26, 2005, 13:05:31 ; Search time 41 Seconds
(without alignments)

605,462 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MMSGAYLVKLVNERPGQAVLM.....SYLDQDNMRYQNAQAKVEA 258

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79:*
1: Trl:*
2: Plr2:*
3: Plr3:*
4: Plr4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	364.5	25.8	397	2 JE0082	GPI-linked recepto
2	130.5	9.2	3635	2 T10053	laminin alpha 5 ch
3	124.5	8.8	1959	1 AGRT	agrin - rat
4	124	8.8	1574	2 T13954	MEGR6 protein - ra
5	123.5	8.7	1964	2 T09059	notch4 - mouse
6	122	8.6	4006	2 T09070	probable tenascin
7	118.5	8.4	1797	2 A55677	laminin beta-2 cha
8	116	8.2	384	2 S25771	gas1 protein - mou
9	116	8.2	2321	2 S76549	notch3 protein - h
10	114	8.1	686	2 JCT7569	Delta-4 protein -
11	114	8.1	1220	2 A56136	jagged protein pre
12	113	8.0	572	2 T29880	hypothetical prote
13	112.5	8.0	1372	2 T25933	hypothetical prote
14	110.5	7.8	476	2 A36478	surface glycoprote
15	110	7.8	4135	2 T42629	tenascin-X - bovin
16	109.5	7.7	1798	2 S53869	laminin beta-2 cha
17	108.5	7.7	2318	2 S45306	notch 3 protein -
18	108	7.6	2918	2 A54105	fibritillin-2 precu
19	107.5	7.6	1203	2 A49175	Notch B protein -
20	107.5	7.6	1955	1 AGCH	agrin precursor -
21	107.5	7.6	2471	2 A49128	cell-fate determin
22	107	7.6	2531	2 A46019	notch-1 protein -
23	107	7.6	3566	1 A40701	tenascin-X precurs
24	106	7.5	335	2 T31560	hypothetical prote
25	105.5	7.5	1184	2 A55184	fibritillin-2 precu
26	105.5	7.5	1801	1 MMRTS	laminin beta-2 cha
27	105.5	7.5	2555	2 A40043	notch protein homo
28	104.5	7.4	242	2 T29699	hypothetical prote
29	104.5	7.4	335	2 T31561	hypothetical prote

30	104.5	7.4	3672	2 T23433	hypothetical prote
31	104.5	7.4	3704	2 T37316	probable laminin a
32	104	7.4	345	2 A53138	gas1 homolog - hum
33	103.5	7.3	335	2 T31559	hypothetical prote
34	103.5	7.3	425	2 T18592	hypothetical prote
35	103.5	7.3	2769	1 UIR0	thryoglobulin prec
36	103	7.3	2139	2 A35672	crumbs protein - f
37	102.5	7.3	600	2 T18593	hypothetical prote
38	102.5	7.3	1664	2 A40136	fibritopellin 1a - s
39	102	7.2	2531	2 S18188	notch protein homo
40	101	7.1	2524	2 A35844	Notch protein - Af
41	100	7.1	728	2 T20561	hypothetical prote
42	100	7.1	2807	2 A57278	fibritillin-2 precu
43	100	7.1	3075	2 S14458	laminin alpha-1 ch
44	99	7.0	1620	2 T27283	hypothetical prote
45	99	7.0	2352	2 T30201	Notch homolog prote

ALIGNMENTS

```

RESULT 1
JE0082
GPI-linked receptor precursor - mouse
N:Alternate names: GFRalpha-3
C:Species: Mus musculus (house mouse)
C:Date: 21-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
C:Accession: JE0082
R:Nomoto, S.; Ito, S.; Yang, L.X.; Kluetz, K.
Biochem. Biophys. Res. Commun. 244, 849-853, 1998
A:Title: Molecular cloning and expression analysis of GFRalpha-3, a novel cDNA related to
A:Reference number: JE0082; M0ID:98205811; PMID:9535755
A:Accession: JE0082
A:Molecule type: mRNA
A:Residues: 1-397 <NOM>
A:Cross-references: UNIPROT:Q35118; DBJ:AB008833; NID:92627159; PIDN:BA23562.1; PID:92627159
C:Comment: This protein plays a distinct role in cell survival and differentiation.
C:Superfamily: Mus musculus GPI-linked receptor
C:Keywords: glycoprotein
F:1-25/Domain: signal sequence #status predicted <SIG>
F:380-397/Region: hydrophobic
F:92,145,306/Binding site: carbohydrate (asn) (covalent) #status predicted

Query Match      25.8%; Score 364.5; DB 2; Length 397;
Best Local Similarity 35.1%; Pred. No. 8,4e-23;
Matches 86; Conservative 26; Mismatches 102; Indels 31; Gaps 7;

QY 20 WSLGQRGSSASTEGNRCVEAEACTADQCQQLRSEVVAOCLGRAGWGPSPSCVRSRGR 79
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 142 WKNUNSLKMLMKRPDSDCLKFMILCTLHKCDRLKRAYGEACSGI-----RCQNHLC 194
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 80 RALRRFPFAGRPALTHALIFCGC--EGPACAEERRQTFAPACAFSGPOLAPSPCLKPLDR 137
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 195 AQLRSFPEKAASHAQGLILCPCAPEDAGCGRRNTTAPSCALPS---VTNCCDLRSP 251
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 138 CERSRRCPRLFAFQASCAPAP--GSRDGPPEGGRCLRAYAGLVGVTVTVNYLDNVA 195
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 252 CQADPLCSRLMDFTQCHPMDLGT---CATEQS-RCIRAYLIGLIGTAMTNFISKWT 307
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 196 RAAWPGCGEASGNRRBECEAPRKLFTNPNCLDGLAIOA-----FDSQSPSVQ 242
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 308 TVALSTCRGSGNLDQECQLERSFSQNPCLVEAIAAKRFRHQLFSGQMDSTFVSVOQ 367
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 243 DQWNP 247
   |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 368 QNSNP 372

RESULT 2
T10053
laminin alpha 5 chain - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 09-Jul-2004

```

Query Match 9.2%; Score 130.5; DB 2; Length 3635;
Best Local Similarity 20.4%; Pred. No. 0.013;
Matches 65; Conservative 21; Mismatches 97; Gaps 12;

RESULT 3
AGRT
agrin - rat
C/Species: Rattus norvegicus (Norway rat)
C/Date: 31-Mar-1993 #sequence_revison 31-Mar-1993 #text_change 09-Jul-2004
C/Accession: JH0399; A38856
R/Rupp: F.; Payan, D.G.; Magill-Solc, C.; Cowan, D.M.; Scheller, R.H.
Neuron 6, 811-823, 1991
A/Title: Structure and expression of a rat agrin.
R/Reference number: JH0399; PMID:91222570; PMID:1851019

F.1-1959/Product: agrin, form 1 #status predicted <AG1>
 F.1-1787,1799-1959/Product: agrin, form 4 #status predicted <AG4>
 F.1-1779,1799-1959/Product: agrin, form 3 #status predicted <AG3>
 F.1-1779,1788-1959/Product: agrin, form 5 #status predicted <AG5>
 F.1-1143,1153-1959/Product: agrin, form 2 #status predicted <AG2>
 F.22-50/Region: hydrophobic
 F.88-137/Domain: kazal proteinase inhibitor homology <KP11>
 F.163-212/Domain: kazal proteinase inhibitor homology <KP12>
 F.236-284/Domain: kazal proteinase inhibitor homology <KP13>
 F.307-356/Domain: kazal proteinase inhibitor homology <KP14>
 F.381-429/Domain: kazal proteinase inhibitor homology <KP15>
 F.446-494/Domain: kazal proteinase inhibitor homology <KP16>
 F.511-559/Domain: kazal proteinase inhibitor homology <KP17>
 F.540-542/Region: motor neuron attachment (L-R-E) motif
 F.596-645/Domain: kazal proteinase inhibitor homology <KP18>
 F.688-739/Domain: laminin-type EGF-like homology <LE1>
 F.742-786/Domain: laminin-type EGF-like homology <LE2>
 F.814-864/Domain: kazal proteinase inhibitor homology <KP19>
 F.869-992/Region: serine/threonine-rich
 F.1084-1086/Region: motor neuron attachment (L-R-E) motif
 F.1147-1215/Region: serine/threonine-rich
 F.1224-1257/Domain: EGF homology <EG1>
 F.1287-1442/Domain: laminin G repeat homology <LG1>
 F.1444-1476/Domain: EGF homology <EG2>
 F.1483-1515/Domain: EGF homology <EG3>
 F.1555-1706/Domain: laminin G repeat homology <LG2>
 F.1733-1747/Domain: EGF homology <EG4>
 F.1807-1959/Domain: laminin G repeat homology <LG3>
 F.197-116,105-137,171-191,180-212,244-263,252-284,316-335,324-356,389-408,397-429,454-473,445-474,1483-1494,1488-1504,1506-1515/Dissulfide bonds: #status predicted
 F.1476,672,827,957/Binding site: carbonylde (Aan) (covalent) #status predicted

Query Match 8.8%, Score 124.5, DB 1, Length 1959;
 Best Local Similarity 23.0%, Pred. No. 0.024;
 Matches 56, Conservative 25, Mismatches 111, Indels 51, Gaps 11;

QY 25 QRGASSTEGNRCYEAABACTADECCQLNSEYVAQCLGRAG-W--RGFGSCYRSRCRR 80
 DB 552 EEAHAGCPCEPAECSCGSGSGSGEDCEQ-----ELCRQGGIWEDESDPCVCDPSCQ 605
 QY 81 ALRFFPAPRPALTHALLFCGCEBPACABERRQTFAPACAFSPGQALP-----PSGLXP 134
 DB 606 SVRPSVPCGSGSVGYTG-TECDLKARCESQDELTVAAQACRGFTLPALLPVAEPHCAQT 664
 QY 135 -----LDRCERSRRCRPLRFAFQASCAPAPGSRDGCPEGEGPCRLRAYA 178
 DB 665 PYGCCQDNFTPAQGVGLAGCPSTCHCNPH-GSYSGTCDPAPGQSCSRPGVGLKRCRCEP 723
 QY 179 GL-VGVVYTPNYLIDNVSAAVAPPCGCEASAGNRREEFAARKLPTNR-----CLD 227
 DB 724 GFANFRGIVTDGH-----SGCTP-CSCDPGAVRDCDEQMTGLCSCRPGVAGPKCGQCPD 777
 QY 228 GAI 230
 DB 778 GGV 780

RESULT 4
 113954
 MEGF6 protein - rat
 CjSpecies: Rattus norvegicus (Norway rat)
 CjDate: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
 CjAccession: T13954
 RjNakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.
 A>Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs
 A|Reference number: Z14126; MUID:98360089; PMID:9693030
 A|Accession: T13954
 A|Status: preliminary; translated from GB/EMBL/DD83
 A|Molecule type: mRNA
 A|Residues: 1-1574 <NA>
 A|Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:93449293; PIDN:BAA32462.1; PID:93449293; strain Sprague-Dawley; brain
 A|Experimental source: strain Sprague-Dawley; brain

APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
TITLE OF INVENTION: Neurturin Receptor
NUMBER OF SEQUENCES: 19

```

/ PRIOR APPLICATION NUMBER: 09/024,665
/ PRIOR FILING DATE: 1998-02-17
/ PRIOR APPLICATION NUMBER: 60/063,258
/ PRIOR FILING DATE: 1997-10-24
/ PRIOR APPLICATION NUMBER: 60/049,818
/ PRIOR FILING DATE: 1997-06-09
/ PRIOR APPLICATION NUMBER: 60/038,839
/ PRIOR FILING DATE: 1997-02-18
/ NUMBER OF SEQ ID NOS: 30
/ SOFTWARE: FASTSEQ for Windows Version 4.0
/ SEQ ID NO: 18
/ LENGTH: 664
/ TYPE: PRT
/ ORGANISM: Artificial Sequence
/ FEATURES:
/ OTHER INFORMATION: This sequence is a fusion protein comprising rat
US-10-357-822-18
Query Match: 33.2%; Score 469; DB 14; Length 664;
Best Local Similarity 43.0%; Pred. No. 5,2e-32;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3

29 ASSTGNNCVAEAECTADEOCQOLRSEYVVAQCLGRAGMRGSGSVRSRRALRRFPAR 88
|||:::||||:::||||:::||||:::||||:::||||:::||||:::||||:::
153 AVTSKSNHCLDAAKACNLNDNCKLRSSYSITCNREIS--PTERCNRRCHALAQFPDR 210
QY 89 GPPALTHALLTCGCEGPAICARRRQTPAPACAFSGPOLAPSPCLKPLDRCEKSRRCRPL 148
|||:::||||:::||||:::||||:::||||:::||||:::||||:::
211 VPSEYTYMLPCSCQDQACARRRRRTIIPSCSYEDKE--KPKCLDLRLSCRTDHLCRSGL 268
QY 149 FAFQSCAPAGSRDGCPEEGSPRCILRAYAGLVGVVTPPNYLDN--VSARVAPWGCEAS 206
269 ADFAHNCAGASRYTITSCPADVYQACLSGYAGMIGPDMTPNVDSNPTGIIVSPMCKNGS 328
Db 207 GNRBECEAFRKLFTRNPCLDGAIQAF 233
|||:::||||:::||||:::||||:::||||:::||||:::||||:::
Db 329 GNMEECEKFLRDPFTEPNCLNNAIQAF 355

RESULT 9
US-10-241-220-62
/ Sequence 62, Application US/10241220
/ Publication No. US20030148408A1
/ GENERAL INFORMATION:
/ APPLICANT: Frantz, Gretchen
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Phillips, Heidi
/ APPLICANT: Spencer, Susan
/ APPLICANT: Polakis, Paul
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wu, Thomas
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
/ TITLE OF INVENTION: TREATMENT OF TUMOR
/ FILE REFERENCE: P5010R1-US
/ CURRENT APPLICATION NUMBER: US/10/241,220
/ CURRENT FILING DATE: 2002-12-13
/ NUMBER OF SEQ ID NOS: 120
/ SEQ ID NO 62
/ LENGTH: 460
/ TYPE: PRT
/ ORGANISM: Homo Sapien
US-10-241-220-62
Query Match: 32.9%; Score 465; DB 14; Length 460;
Best Local Similarity 41.9%; Pred. No. 7,8e-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3

QY 33 EGNRCVEAEACTADEOCQOLRSEYVVAQCLGRAGMRGSGSVRSRRALRRFPAR 92
|||:::||||:::||||:::||||:::||||:::||||:::||||:::
Db 145 GKNNCCLDAKACNLDDICKYRSAYITPCTTSV---SNDVCNRRCHALAQFPDKVPAK 201

```

```

0Y 93 LTHALLFCGCEBPACHERRORTFAPAPCAISGQOLAPSPCLKPLRDERBSRCKPRLEPAFQ 152
Db 202 HSYGMLFSCSRDIACIERRROTIVPCSYE--EREKPCNTLIDOSCKTYIICSRADPF 259
0Y 153 ASCAPGSRDGCPEEGCPRCRAVYGLVTVTPYULNVNSARVA PMGCEASGNREE 212
Db 260 TNCQESBSVSSCLKENYADCLLAISGLIGTVWTPYVITDSSLSLVAPMCDCSNSGNDLEE 319
0Y 213 CEAFKRLFTRNPCLDGAIQAFDSSQPSVLQDQWNP 247
Db 320 CLKFLNFKDNTCLKNALIQAFNGSVDVTV---MOP 351

```

```

RESULT 10
US-10-872-972-62
: Sequence 62: Application US/10872972
: Publication NO. US2004022927A1
: GENERAL INFORMATION:
: APPLICANT: Frantz,Gretchen
: APPLICANT: Hillan,Kenneth J.
: APPLICANT: Phillips,Heidi
: APPLICANT: Polakts,Paul
: APPLICANT: Spencer,Susan
: APPLICANT: Williams,P.Mickey
: APPLICANT: Wu,Thomas
: APPLICANT: Zhang,Zemin
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
: TITLE OF INVENTION: TREATMENT OF TUMOR
: FILE REFERENCE: P5010R1-US
: CURRENT APPLICATION NUMBER: US/10/872,972
: CURRENT FILING DATE: 2004-06-21
: PRIOR APPLICATION NUMBER: US/10/241,220
: PRIOR FILING DATE: 2002-09-11
: NUMBER OF SEQ ID NOS: 120
: SEQ ID NO 62
: LENGTH: 460
: TYPE: PRT
: ORGANISM: Homo Sapien
US-10-872-972-62

```

Query Match	Similarity	Score	465;	DB	17;	Length	460;
Best Local	Similarity	41.9%;	Pred.	No.7.8e-32;			
Match	Conservative	30;	Mismatch	87;	Indels	8;	Gaps
Qy	33	EGNRCVEAAEACTADEBOCCOOLRSEYVAOCLIGRAGMRGPGSVRSRCRALRFFAAGPPA	92				
Db	145	KGNNCTLDAKACNLDDICCKYRSAYITPCTTSV---SNDVCNRRKKCHALLRGFFDYPAK	201				
Qy	93	LTHALLFGCCBPACAEERRRQTFAPAPCASSGPOLAPSPCLKPLDRBERSRCRPLPAFO	152				
Db	202	HSYGLMFCSCRDIACTERRRQTTVPACSYE--EREKPCNTLQDSCKTYNTICSRADPF	259				
Qy	153	ASCAAPGSRDCCPEEGGPRCLRAYAGLVGTVTPPYTLNDVNSARVAPMWCSEASGNRREE	212				
Db	260	TNCGESRSVSSCLKENYADCLLAYSGLLGTWVTPTYIDSSSLSVAPMWCDSNSGMDLEE	319				
Qy	213	CEAFRLKFTFRNPCLDGAIGAPSSSGQSVLYQDQNP	247				
Db	320	CLKFLNFFKDNCTCLKNALQAFNGSDVTV---WQP	351				

RESULT 11
US-10-872-991-62
; Sequence 62, Application US/10872991
; Publication No. US20040242860A1
; GENERAL INFORMATION:
; APPLICANT: Frantz, Gretchen
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Phillips, Heidi
; APPLICANT: Polakits, Paul
; APPLICANT: Spencer, Susan
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wu, Thomas

```

APPLICANT: Zhang, Zemin
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
TREATMENT OF TUMOR
FILE REFERENCE: P5010R1-US
CURRENT APPLICATION NUMBER: US/10/872,991
CURRENT FILING DATE: 2004-06-21
PRIOR APPLICATION NUMBER: US/10/241,220
PRIOR FILING DATE: 2002-09-11
NUMBER OF SEQ ID NOS: 120
SEQ ID NO 62
LENGTH: 460
TYPE: PRT
ORGANISM: Homo Sapien.
US-10-872-991-62

```

Query Match	32.9%	Score 465	DB 17	Length 460
Best Local Similarity	41.9%	Pred. No. 7,8e-32		
Matches	90	Conservative 30	Mismatches 87	Indels 8
			Gaps 3	
QY	33	EGNRCVEAAEACTADEOCQOLRSEYVAOCLGRBAGRGSGSCVSRSHCRRLRRFPARGPPA	92	
DB	145	GNKNCICLDAAKACNLDIDICCKYRSATITTCITSV---SNDVCRRRCCHRALROQFPDKVPARK	201	
QY	93	LTHALLFCGCGGAPCAERRRQTFAPACAFSGQQLAPSGCLRPDLRCERSRRRCPRLFAQ	152	
DB	202	HSYGLGFLSCSDIATERRRQITVFVCSYE--EREKPCMLNIQDSCKTNYICRSRLADFF	259	
QY	153	ASCAPAPSGRDGCEBEGGPRCLRAYAGIVGTVTENTYLDNVSARVAPMGCEASGNRBE	212	
DB	260	TNCPDSRSVSSCLKENYADCLLAYSGLIGVTMTNTNYIDSSLSVAAPMCDGCSGNDLBE	319	
QY	213	CEAPRKLFTRNPLCDLGAQAFDSSQPSVTLQDOOMP	247	
DB	320	CLKPLNFPKNDYCLKNALQAFGNGSDVTV---WQP	351	

```

RESULT 12
US-10-155-693-10
; Sequence 10, Application US/10155693
; Publication No. US20030175876A1
; GENERAL INFORMATION:
; APPLICANT: FOX, GARY M.
; APPLICANT: JING, SHUQIAN
; APPLICANT: WEN, DUNZHAI
; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
; FILE REFERENCE: A-401C
; CURRENT APPLICATION NUMBER: US/10/155,693
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US/08/837,199
; PRIOR FILING DATE: 1997-04-14
; PRIOR APPLICATION NUMBER: US 60/015,907
; PRIOR FILING DATE: 1996-04-22
; PRIOR APPLICATION NUMBER: US 60/017,221
; PRIOR FILING DATE: 1996-05-09
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10

```

```

NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser.
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(537)
OTHER INFORMATION: No. US20030175876A1e="1 to 537 is -235 to 301 of Figure 5 21a1com
FEATURE:
NAME/KEY: misc_feature
LOCATION: (550)..(550)
OTHER INFORMATION: N in position 550 indicates any nucleic acid
US-10-155-693-10

```

```
Query Match      32.9%; Score 465; DB 14; Length 463;
Best Local Similarity 41.9%; Pred. No. 7.8e-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVEAAEACTADDECOQLRSEVVAQCLGRAGWRGSGSVRSRCRRALRRFFARGPPA 92
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 150 KNNNCIDAAKACNLDIDCKKRSAYITPCTTSV---SNDVCRKRCKHAKLRQFPDKVPK 206
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 93 LTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPPSCLKPLDRCERSRRCPRLFAFQ 152
   ::|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 207 HSYGMLFCSCRDIACTERRRQTIIVPCSYE--EREKPNCLINQDSCKTYICRSRLADPF 264
   ::|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 153 ASCAPAPSGRDGCPBEGPRCLRAYAGLVGTVPNTYLDNVSARVAPMCGCEASGNRREE 212
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 265 TNCQPEBSRSVSSCKENYADCLAYSGLIGVTWTPNTYIDSSLSVAFWCDSNSGNDLE 324
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 213 CEAFKRLFTRNPCLDGAIQAFDSSQPSVYLQDQNP 247
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 325 CLKFLNPFKDMNTCLKNAIQAFNGSDVTY---WQP 356
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

```
RESULT 13
; Sequence 12, Application US/10155693
; Publication No. US20030175876A1
; GENERAL INFORMATION:
; APPLICANT: FOX, GARY M.
; APPLICANT: JING, SHUOJIAN
; APPLICANT: MEN, DUANZHAI
; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
; FILE REFERENCE: A-401C
; CURRENT APPLICATION NUMBER: US/10/155,693
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US/08/837,199
; PRIOR FILING DATE: 1997-04-14
; PRIOR APPLICATION NUMBER: US 60/015,907
; PRIOR FILING DATE: 1996-04-22
; PRIOR APPLICATION NUMBER: US 60/017,221
; PRIOR FILING DATE: 1996-05-09
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 463
; TYPE: PRT
; ORGANISM: HUMAN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(539)
; OTHER INFORMATION: No. US20030175876A1e="1 to 539 is -237 to 301 of Figure 5 21bcom
US-10-155-693-12
```

```
Query Match      32.9%; Score 465; DB 14; Length 463;
Best Local Similarity 41.9%; Pred. No. 7.8e-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVEAAEACTADDECOQLRSEVVAQCLGRAGWRGSGSVRSRCRRALRRFFARGPPA 92
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 150 KNNNCIDAAKACNLDIDCKKRSAYITPCTTSV---SNDVCRKRCKHAKLRQFPDKVPK 206
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 93 LTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPPSCLKPLDRCERSRRCPRLFAFQ 152
   ::|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 207 HSYGMLFCSCRDIACTERRRQTIIVPCSYE--EREKPNCLINQDSCKTYICRSRLADPF 264
   ::|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 153 ASCAPAPSGRDGCPBEGPRCLRAYAGLVGTVPNTYLDNVSARVAPMCGCEASGNRREE 212
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 265 TNCQPEBSRSVSSCKENYADCLAYSGLIGVTWTPNTYIDSSLSVAFWCDSNSGNDLE 324
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 213 CEAFKRLFTRNPCLDGAIQAFDSSQPSVYLQDQNP 247
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 325 CLKFLNPFKDMNTCLKNAIQAFNGSDVTY---WQP 356
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

```
RESULT 14
US-10-872-161-10
; Sequence 10, Application US/10872161
; Publication No. US20040235714A1
; GENERAL INFORMATION:
; APPLICANT: FOX, GARY M.
; APPLICANT: JING, SHUOJIAN
; APPLICANT: MEN, DUANZHAI
; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
; FILE REFERENCE: A-401D
; CURRENT APPLICATION NUMBER: US/10/872,161
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: US/08/866,354
; PRIOR FILING DATE: 1997-05-30
; PRIOR APPLICATION NUMBER: US 60/015,907
; PRIOR FILING DATE: 1996-04-22
; PRIOR APPLICATION NUMBER: US 60/017,221
; PRIOR FILING DATE: 1996-05-09
; PRIOR APPLICATION NUMBER: US 08/837,199
; PRIOR FILING DATE: 1997-04-14
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 463
; TYPE: PRT
; ORGANISM: HUMAN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser.
US-10-872-161-10
```

```
Query Match      32.9%; Score 465; DB 17; Length 463;
Best Local Similarity 41.9%; Pred. No. 7.8e-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVEAAEACTADDECOQLRSEVVAQCLGRAGWRGSGSVRSRCRRALRRFFARGPPA 92
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 150 KNNNCIDAAKACNLDIDCKKRSAYITPCTTSV---SNDVCRKRCKHAKLRQFPDKVPK 206
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 93 LTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPPSCLKPLDRCERSRRCPRLFAFQ 152
   ::|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 207 HSYGMLFCSCRDIACTERRRQTIIVPCSYE--EREKPNCLINQDSCKTYICRSRLADPF 264
   ::|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 153 ASCAPAPSGRDGCPBEGPRCLRAYAGLVGTVPNTYLDNVSARVAPMCGCEASGNRREE 212
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 265 TNCQPEBSRSVSSCKENYADCLAYSGLIGVTWTPNTYIDSSLSVAFWCDSNSGNDLE 324
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 213 CEAFKRLFTRNPCLDGAIQAFDSSQPSVYLQDQNP 247
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB 325 CLKFLNPFKDMNTCLKNAIQAFNGSDVTY---WQP 356
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

```
RESULT 15
US-10-872-161-12
; Sequence 12, Application US/10872161
; Publication No. US20040235714A1
; GENERAL INFORMATION:
; APPLICANT: FOX, GARY M.
; APPLICANT: JING, SHUOJIAN
; APPLICANT: MEN, DUANZHAI
; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
; FILE REFERENCE: A-401D
; CURRENT APPLICATION NUMBER: US/10/872,161
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: US/08/866,354
; PRIOR FILING DATE: 1997-05-30
; PRIOR APPLICATION NUMBER: US 60/015,907
; PRIOR FILING DATE: 1996-04-22
; PRIOR APPLICATION NUMBER: US 60/017,221
; PRIOR FILING DATE: 1996-05-09
; PRIOR APPLICATION NUMBER: US 08/837,199
; PRIOR FILING DATE: 1997-04-14
```

NUMBER OF SEQ ID NOS: 61
SOFTWARE: PatentIn version 3.2
SEQ ID NO: 12
LENGTH: 463
TYPE: PRT
ORGANISM: HUMAN
US-10-872-161-12

Query Match 32.9%; Score 465; DB 17; Length 463;
Best Local Similarity 41.9%; Pred. No. 7.8e-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVEAAEACTADECCOOLRSEVVAQCLGRAGWPGSCVRSRCBRALRRPFARGPPA 92
DB 150 KANNCLDAKAKACMLDIDICKKYSAYITPCTTSV--SNDVCNRRKCHKALRQPFDPKPAK 206
QY 93 LTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPPSCIKPLDRCESRRCRPRLFAPQ 152
DB 207 HSYGMLFCSCRDIACTERRRQTI VPCSYE--EREKPNCLNLQDSCKTNYICRSLADPF 264
QY 153 ASGAPAPGSRDGCPEEGGPRCLRAYAGLVGTVTPNYLDNVSAKVAAPWCGCEASGNRREB 212
DB 265 TNCQPESSRSVSSCKENYADCLAYSGLIGTVTPNYIDSSLSVA PWCDCSNSGNDLEB 324
QY 213 CEAFRLKLTFRNPCLDGAIOAPDSQPSVLDQDNKP 247
DB 325 CLKFLNFFKDNVTLKNAIQHFGNGSDVTY--MQP 356

Search completed: January 26, 2005, 13:28:26
Job time : 149 secs

